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ABSTRACT 
 
We demonstrate that a firm’s ability to innovate is predictable, persistent, and relatively 
simple to compute, and yet the stock market ignores the implications of past successes 
when valuing future innovation.  We show that two firms that invest the exact same in 
research and development (R&D) can have quite divergent, but predictably divergent, 
future paths.  Our approach is based on the simple premise that while future outcomes 
associated with R&D investment are uncertain, the past track records of firms may give 
insight into their potential for future success.   We show that a long-short portfolio 
strategy that takes advantage of the information in past track records earns abnormal 
returns of roughly 11 percent per year.  Importantly, these past track records also predict 
divergent future real outcomes in patents, patent citations, and new product 
innovations.      
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Firms engage in a variety of activities.  Some of these activities are straightforward, and 
easy to assess how they will impact firm value (e.g., maintenance capital expenditures).  
However, some of these activities, while crucially important for the discounted value of a 
firm’s future cash flows, are quite uncertain and difficult to decipher how they will 
ultimately impact firm value.  Although hard to assess, it may still be the case that 
analysis of publicly available information can give substantive insight into reducing the 
uncertainty surrounding these actions.   
The activity at the heart of our investigation is investment in research and 
development (R&D).  Given that R&D stimulates innovation and technological change, 
which can in turn lead to improvements in productivity, living standards, and 
economic output, the proper allocation of R&D investment in the economy is a critical 
task of the market.  And yet, this task is made difficult by the fact that R&D investment 
is such a highly uncertain activity.  Perhaps as a result of this uncertainty, R&D 
investment has increasingly become a market-driven activity.   Although the share of 
R&D as a percentage of GDP has remained roughly constant (between 2-3%) since the 
1960s, the composition of R&D investment in the economy has shifted dramatically, away 
from federal spending and toward private sector spending.
1   Since the late 1980s, for 
example, virtually all of the increases in total R&D spending have come from the private 
sector.   The market’s role in allocating R&D investment has become more important 
than ever. 
In this paper we demonstrate that the stock market is unable to distinguish 
between “good” and “bad” R&D investment, despite the fact that successful innovation 
is in fact predictable.  We show that two firms that invest the same amount in R&D can 
have quite divergent, but predictably divergent, future paths.   Our approach is based on 
the simple premise that while future outcomes associated with R&D investment are 
uncertain, past information about firms’ success at R&D gives us insight into their 
potential for future success. 
Our empirical strategy proceeds from the notion that past track records represent 
one simple way to gauge the future prospects of firms.  Some firms are skilled at certain 
activities, and some are not, and this skill may be persistent over time.  Using this idea 
                                                 
1 See Congressional Budget Office’s 2005 report entitled “R&D and Productivity Growth.”  
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as the starting point for our analysis, we examine the predictability of firm-level R&D 
investment track records for future returns and future real outcomes.  We find that 
although R&D success is predictable, persistent, and relatively simple to compute, the 
market largely ignores the information embedded in past track records.   
  Our identification of past R&D success is based on a simple framework of using a 
firm’s past ability in translating R&D into something the firm values.  We then take this 
“ability” of a firm at R&D and interact it with the amount of research the firm is 
actually undertaking.  For instance, we examine the outcomes of those firms that have 
been quite good at R&D and are investing heavily in R&D with firms investing identical 
amounts in R&D, but that have poor past track records.  If the market correctly takes 
into account the prior track records’ implications for future success, then whether firms 
are optimally choosing levels of R&D or not, the market should impound relevant 
information regarding innovation into prices.  In fact, the market could even be 
completely incorrect in impounding the impact of every firm’s R&D expenditures (as they 
do have uncertain effects on future firm value), but this would still have no implication 
for predictability based on past information, as the market will sometimes overvalue and 
sometimes undervalue this innovation.     
  We find that the market consistently misvalues innovation in an ex-ante, 
predictable way.  Specifically, the market does not take into account the information in 
firms’ past R&D abilities.  Firms that have been successful in the past and that invest 
heavily in R&D as a percentage of sales (“GoodR&D” firms) earn substantially higher 
future stock returns than firms that invest identical amounts in R&D, but that have poor 
past track records (“BadR&D” firms).  A portfolio of GoodR&D firms earns equal- and 
value-weighted excess returns of 135 basis points per month (t=2.76) and 122 basis points 
per month (t=2.61), and 4-factor alphas of 90 basis points per month (t=3.11) and 78 
basis points per month (t=2.27), respectively.  In contrast, the portfolio of firms with 
poor past track records but that invests the same amount of R&D (BadR&D) earns -15 
basis points per month in 4-factor value-weighted alpha (t=0.56).  The spread portfolio 
that takes identical high R&D-level portfolios, but exploits differences in past track 
records, has a 4-factor alpha of 93 basis points per month (t=2.30) or over 11% per year.  
Returns to the “GoodR&D” (and spread) portfolios are large and significant in the first  
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year, and then returns remain slightly positive but basically plateau in the second and 
third years, with no reversal.  This suggests that we are not capturing a form of 
overreaction, but instead that the embedded information regarding innovation that the 
market is misvaluing is important for fundamental firm value.  
  Our findings add to a growing literature highlighting the market’s inability to 
properly value investments in R&D.  On one hand, some researchers argue that investors 
may overestimate the benefits from R&D or simply ignore the fact that many R&D 
investments are not profitable (Jensen (1993)), leading to the overpricing of R&D-
intensive firms.  For example, Lakonishok, Shleifer, and Vishny (1994) find that growth 
stocks earn low future returns, while Daniel and Titman (2006) show that this growth 
stock underperformance is concentrated in stocks with significant “intangible” 
information, consistent with market overreaction to intangible information that is 
difficult to interpret.
2  However, the recent evidence on firm-level R&D activity suggests 
that, if anything, the market appears to underreact to the information contained in R&D 
investments.  For example, Chan, Lakonishok, and Sougiannis (2001) and Lev and 
Sougiannis (1996) demonstrate that firms with high ratios of R&D relative to market 
equity earn high subsequent returns; Eberhart et al. (2004) find that large increases in 
R&D expenditures predict positive future abnormal returns; and Hirshleifer et al. (2010) 
show that firm-level innovative “efficiency” (measured as patents scaled by R&D) 
forecasts future returns.
3  We show that our results are unaffected by the inclusion of 
these measures in our tests, and are roughly 3 times larger in magnitude than the findings 
in, for example, Eberhart et al. (2004) and Hirshleifer et al. (2010), suggesting that our 
approach is picking up a new and previously undetected pattern in the cross-section of 
stock returns associated with the market’s misvaluation of high R&D ability firms.   
To combat the concern that our results are due to data mining, we run a series of 
out-of-sample tests on our findings.  We find that our classification of high ability R&D 
firms is also predictive of future returns in an international sample (including the UK, 
Japan, and Germany) and in the period immediately preceding our sample period (1974-
                                                 
2 See also Daniel, Hirshleifer, and Subrahmanyam (1998, DHS)’s distinction between public and private 
information.  DHS theorize that investors are overconfident about the precision of their private signals, and 
therefore overreact to intangible private information and underreact to tangible public information.   
3 See also Porter (1992), Hall (1993a), and Hall and Hall (1993), who argue that investors may be myopic 
and discount the cash flows from R&D capital at a very high rate, leading to underpricing.  
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1980).  For example, when we employ our baseline Fama-MacBeth cross-sectional 
regression on an international sample that pools together the universe of stocks from the 
UK, Japan, and Germany (using dollar-returns on all stocks), we find a coefficient on 
R&Dhigh*abilityhigh of 0.501 (t=2.24), which is similar in magnitude and significance to our 
U.S. findings.  In addition, while our baseline U.S. portfolio results are driven by a small 
number of firms (the High Ability-High R&D portfolio described above contains an 
average of 10 stocks per month), the percentage of market capitalization in the portfolio 
(0.71% of the stock market’s annual value on average) is larger than that of the “small 
value” portfolio (0.50% of the stock market’s annual value on average) that is featured in 
hundreds of asset pricing papers, and which remains one of the most studied anomalies in 
the literature. 
  Lastly, we run a series of tests designed to pinpoint the mechanism behind our 
results.  First, we explore real outcomes associated with our high R&D ability firms.  
Specifically, we show that the firms that we classify as high ability firms and that invest 
heavily in R&D also produce tangible results with their research and development efforts.  
They generate significantly more patents, achieve significantly more patent-citations, and 
develop significantly more new products than firms that invest the same levels of R&D, 
but have poor track records.  In addition, we demonstrate that high ability firms exhibit 
significant persistence in R&D skill, that this skill may be positively related to the 
presence of a founder, and that the market’s failure to understand the implications of 
R&D track records is related to heterogeneity in information provision by firms.  For 
example, we show that the predictability in future returns is significantly lower for high 
ability firms who provide more earnings guidance; under the assumption that firms that 
provide more earnings guidance are also likely to provide more information to investors 
more generally (as in Jones (2007)), these findings suggest that cross-sectional variation 
in information opacity may help explain why the market fails to properly understand the 
information embedded in firms’ past track records.     
   
I. Data and Summary Statistics 
  We combine a variety of data sources to create the sample we use in this paper.  
We draw monthly stock returns, shares outstanding, and volume capitalization from  
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CRSP, and extract a host of firm-specific accounting variables, such as research and 
development (R&D) expenditures, sales and general administrative expenses (SG&A), 
book equity, etc., from Compustat.  We combine these items with firm-level patent data 
drawn from the NBER’s U.S. Patent Citations Data File,
4 segment-level product data 
from the Compustat Segment Data File, earnings’ guidance data from First Call and 
CEO founder data from Fahlenbrach’s (2009) hand-collected data and the Corporate 
Data Library. We draw international stock return data from Datastream and accounting 
data from Worldscope. We filter the datastream stock return data and identify common 
stocks using the procedures and suggestions outlined in Ince and Porter (2006) and 
Griffin, Nadari, and Kelly (2010). 
  Table I presents summary statistics for the sample we use in this paper (Panel B), 
compared to the entire universe of stocks on CRSP (Panel A), over our July 1980 to 
December 2009 sample period.  Our sample includes all NYSE, AMEX, and Nasdaq 
common stocks (CRSP share code 10-12) with a valid (i.e., non-missing) R&D estimate in 
a given year, as well as a valid estimate for the "Ability" measure that features in our 
analysis.   
The notion of “Ability” is meant to capture simply how good a firm is at turning 
R&D expenditures into something the firm values.  We have run our tests using a 
number of measures of what the firm “values” and our results are robust to the various 
measures we have tried.  The measure we show in the paper is how R&D translates into 
actual future sales revenue of the firm.
5  One additional concern may be the horizon we 
use to identify the translated effect of R&D on future outcomes.  As we describe below, 
we try to be flexible on this dimension and use up to a five-year lag in measuring the 
impact of past R&D expenditures on future firm outcomes.  
Thus, for sales (reported in the paper), we compute firm “Ability” by running 
rolling firm-by-firm regressions of firm-level sales growth (defined as log(Salest/Salest-1)) 
on lagged R&D (R&Dt-j/Salest-j; where j=1,2,3,4,5).  We run separate regressions for 5 
                                                 
4 The patent data is collected, maintained, and provided by the National Bureau of Economic Research 
Patent Data Project.  All data files we use, along with documentation, can be obtained from the project’s 
website at https://sites.google.com/site/patentdataproject/Home. 
5 As mentioned, we have used various measures of profitability, such as return-on-assets (ROA), instead of 
sales growth.  The results are very similar in magnitude and significance.  For instance, the analog of the 
Spread portfolios from Table III using ROA have monthly 3- and 4-factor alphas of 51 and 59 basis points 
(t=2.10 and 2.39), respectively.  
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different lags of R&D (i.e., R&D from years t-1, t-2, t-3, t-4, and t-5); we then take the 
average of these five R&D regression coefficients as our measure of ability (regression 
specification shown in Table II).  Again, the idea behind this measure is to isolate the 
extent to which a given firm successfully converts its R&D investments into future sales.  
We have analyzed a variety of different specifications here, and our results are robust to 
these permutations; for example, running a single regression for each firm of sales growth 
on the average of the past 5 years of R&D, and using this single coefficient as our 
measure of ability yields similar, and often stronger, results (we show these results in 
Appendix Table A5). 
In estimating a firm’s ability, for every firm in each year we use 8 years of past 
data for each firm-level regression, and we then run these regressions on a rolling basis 
each year using the prior 8 years of data.  For each regression, we require a minimum of 
6 (75%) non-missing R&D observations and that at least half the R&D observations are 
non-zero; otherwise, we set the slope coefficients to missing values.
6  Panel B of Table I 
indicates that our final sample is quite similar to the overall sample of CRSP stocks.  
Comparing characteristic-by-characteristic, our sample does contain slightly larger stocks, 
with a modest growth tilt relative to the overall sample of CRSP stocks. While the stocks 
in our sample are slightly less levered, the price momentum, turnover, and stock volatility 
are nearly identical to the entire universe.  Overall, the differences between the two 
samples appear small. 
  Panel A of Table II presents the full-sample sample averages of the rolling firm-by-
firm regression coefficients that form the basis of our ability measure.  The average 
ability estimate is 3.33, with an average sales growth of roughly 7%, while average R&D 
expenditures equate to roughly 17% of sales.  
We then turn to some diagnostics of our Ability measure.  If we are truly 
capturing a meaningful measure of a firm’s ability at Research and Development, we 
                                                 
6 We have analyzed back-windows of 6-10 years of past data as well, with the trade-off coming between 
fewer data points required (so more observations estimated) per firm, but less reliable estimates, compared 
with, say requiring 10 years of data, which allows fewer observations to be estimated (and more auto-
correlated estimates as only 1 observation changes per estimation period), but more precise estimates.  We 
choose the mid-point of using 8 years of past data.  The results look very similar across these estimation 
windows, in magnitude and significance. In fact, in magnitude the results for both 6- and 10-year windows 
are a bit larger (for instance the value-weighted Spread portfolio using a 10-year back window has 4-factor 
alpha abnormal returns of 101 basis points per month (t=2.49) as opposed to the 93 basis points reported 
in Table III).         
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might expect to see some level of persistence in this measure (i.e., it would be odd to see 
firms simply jump from being classified as “good” at R&D to “poor” at R&D, and back, 
year after year).  Panel B of Table II examines this issue by showing the annual 
persistence in a firm’s ability quintile assignment, for yearly lags out to 5 years.  We find 
that firms in the highest quintile of ability remain in this same top quintile in the 
following year 70% of the time.
7  Overall, Panel B demonstrates that there is substantial 
persistence in firm-level R&D ability, but that firms do transition out (on average) of the 
high ability category within several years.
8 
   
II. Results 
A. Portfolio Returns 
  In this section we examine average returns on portfolios formed using information 
about both a firm’s ability and its level of R&D.  We scale R&D by sales, and use three-
way sorts using the same methodology of Fama and French (1996), namely: R&Dlow 
contains all stocks below the 30th percentile in R&D (but who have R&D greater than 
zero), and R&Dhigh contains all stocks above the 70th percentile in R&D.  We compute 
firm-year ability as described earlier, using the annual average of the rolling regression 
coefficients of sales growth on 5 lags of R&D (scaled by sales).
9  We include all NYSE, 
                                                 
7 To construct a baseline to compare this 70% against, we simulate our data using the parameters of our 
data (i.e., assuming a world with the exact same number of firms, and using the same rolling windows for 
these firms), but with R&D and sales replaced with standard normal variables. We run 1,000 simulations, 
and the averages of the 1,000 simulations are reported in the Internet Appendix Table A1.  Comparing this 
simulated ability measure’s persistence to the actual data, the 70% persistence in our high ability quintile is 
significantly higher than would be expected by chance: e.g., the Monte Carlo simulation results in 
Appendix Table A1 indicate that one should expect a firm in the top quintile to remain in the top quintile 
in the following year only 54% of the time; thus the 70% persistence of our actual ability measure is 
roughly 30% larger in magnitude than the simulated persistence expected by chance.  
8 This level of persistence stands in contrast to the lack of persistence shown in the mutual fund 
performance literature (see, for example, Brown, Goetzmann, Ibbotson, and Ross (1992), Malkiel (1995), 
Wermers (1997), Carhart (1997), and Daniel et al. (1997)) and the modest persistence shown in the hedge 
fund performance literature (see, for example, Agarwal and Nail (2000, 2004), Fung, Hsieh, Nail, and 
Ramadorai (2008), Kosowski, Nail, and Teo (2007), and Teo (2011)). 
9 In order to further test the robustness of our measure, we perform a number of falsification exercises.  
First, if we replace R&D with a non-negative random variable with the same time-series mean and stand 
deviation as the typical stock’s R&D in the sample (keeping every other aspect of the sample the same), we 
find virtually no spread in returns.  Also, if we just remove R&D from the ability estimation altogether 
(and simply use 1/sales instead), we again find no spread in returns.  Finally, if we use raw R&D when 
estimating ability instead of scaled R&D, we still find significant (although slightly smaller) portfolio 
spreads (=43 basis points, t=1.81).  These results indicate that our findings are not driven by our choice of  
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AMEX, and Nasdaq stocks from July 1978 to December 2009 with lagged share prices 
above $5 into these portfolios, and rebalance the portfolios yearly.   
We characteristically-adjust returns (as in Daniel et al. (1997)) using either 25 
size/book-to-market benchmark portfolios, or 125 (5x5x5) size/book-to-
market/momentum benchmark portfolios.  We also compute three- and four-factor alphas 
(as in Fama and French (1996), and Carhart (1997)) by running time-series regressions of 
excess portfolio returns on the market (MKT), size (SMB), value (HML), and momentum 
(UMD) factor returns.  In addition to these risk adjustments, we also calculate an 
industry benchmark-adjusted return.  If the ability measure is somehow sorting on 
industry (so the High Ability firms are disproportionately from one industry), we may be 
inadvertently sorting on an industry characteristic unrelated to our ability explanation.  
To combat this potential problem, each month we compute each firm’s return subtracting 
out its industry’s return over the same month.  Thus, these industry excess returns will 
control for any characteristic of a firm (High or Low Ability) shared by its industry, and 
isolate only its abnormal returns relative to other firms in the same industry.
10  Lastly, as 
we will compare the returns of two firms that have both been spending a large amount on 
R&D (but with varying abilities), we have no selection bias in terms of firms that decide 
to engage (or not) in R&D.  This also rules out any general story that there has been an 
unexpected positive trend for innovative firms over the past 30 years, as that would show 
up in all high R&D firms.  Equivalently, we compare the returns within High Ability 
firms, varying levels of R&D, to rule out the possibility of High Ability sorting an 
unobserved risk.   
  Table III reports average stock returns for monthly portfolio sorts, and illustrates 
our first main result: stocks that exhibit high ability in the past and that spend a large 
amount on R&D (i.e., stocks in the Abilityhigh / R&Dhigh portfolio, which we will call the 
"GoodR&D" portfolio) outperform in the future.  This result holds for both equal- and 
value-weight portfolio returns, and for excess returns, characteristically-adjusted returns, 
industry-adjusted returns, and 3- and 4-factor alphas.  Further, the magnitude of this 
outperformance is large: Panel A shows that the GoodR&D portfolio earns 135 basis 
                                                                                                                                                                
scaling variable, but instead suggest we are capturing an important aspect of R&D spending.  
10 We assign firms into 17 industries, as defined in Fama and French (1997).  Running it using the 10-, 12-, 
30-, or 49-industry defined portfolios has no effect on the magnitude or significance of the results.   
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points per month (t=2.76) in equal-weight excess returns, and 122 basis points per month 
(t=2.61) in value-weight excess returns, which translates to 17.5% and 15.7% annually, 
respectively.  In addition, the long-short portfolio spread (Spread) between stocks in the 
GoodR&D portfolio and those stocks that exhibit low  ability in the past but which 
continue to spend a large amount on R&D (i.e., stocks in the Abilitylow / R&Dhigh 
portfolio, which we will call the "BadR&D" portfolio), is large and significant.  For 
example, Panels A and B shows that the raw equal-weight spread is 73 basis points per 
month (t=2.61), and the raw value-weight spread is 90 basis points per month (t=2.30), 
which translates to 9.1% and 11.4% annually, respectively.  Again this result holds for 
both equal- and value-weight portfolio returns, and for characteristically-adjusted returns, 
industry-adjusted returns, and 3- and 4-factor alphas.  Note that the two components of 
this spread portfolio (i.e., the GoodR&D portfolio vs. the BadR&D portfolio) are very 
similar on other characteristics (e.g., in percentiles, the average size (0.46 vs. 0.43), book-
to-market (0.31 vs. 0.38), leverage (0.26 vs. 0.25), momentum (0.56 vs. 0.53), volatility 
(0.53 vs. 0.49), turnover (0.72 vs. 0.69), and past R&D growth (0.65 vs. 0.69) are 
virtually the same for both portfolios). 
Panel C of Table III presents additional characteristics of these portfolios.   
Specifically, the four-factor loadings in Panel C suggest that the GoodR&D portfolio 
loads negatively on value and momentum and positively on size, meaning that the stocks 
in this portfolio are typically large, growth stocks with poor past returns.  Meanwhile the 
spread portfolio has no significant loadings on any of the four factors, indicating that the 
returns to this portfolio do not covary with any of these well-known factors.  In addition, 
while Panel C reveals that the High Ability-High R&D portfolio contains an average of 
only 10 stocks per month, the percentage of combined market capitalization in this 
portfolio (0.71% of the stock market’s annual value on average) is larger than that of the 
“small value” portfolio (0.50% of the stock market’s annual value on average) that is 
featured prominently in the literature.   
The results here are not sensitive to the particular breakpoints chosen; sorting 
based on quintiles or quartiles produces very similar (sometimes even a bit stronger) 
results.  For example, the equal-weighted DGTW characteristically adjusted-spread 
return using 5x5 sorts is 120 basis points per month (t=2.29), while Appendix Tables A4  
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show that this same spread return using 4x4 sorts is 95 basis points per month (t=3.57).  
We have additionally tried coarser sorts, as in Appendix Table A3, where we simply split 
by median level of R&D.  These sorts, while having less power to distinguish between 
R&D spending levels, again yield the same result: High Ability firms that engage in more 
R&D spending outperform Low Ability firms that also are above median spenders on 
R&D.  The analogous DGTW spread portfolio returns 55 basis points per month 
(t=3.70).  Further, the High Ability-High R&D contains an average of 29 stocks per 
month, with an average market capitalization of 1.93%.  This is larger than the combined 
market capitalization of value quintile portfolios #1-3 (which together account for 1.71% 
[=0.50+0.49+0.72] of total market capitalization on average, and which collectively 
account for most (80%) of the value premium from 1963-2009).
11  Lastly, we also present 
results in Appendix Table A9 using “conditional sorts” (as opposed to the independent 
sorts we use for most of the paper) which sort stocks based on Ability, and *then* by 
R&D within each Ability bin.  This approach forces the number of stocks to be equal in 
each portfolio bin, and by doing so increases the number of stocks in the “High-High” 
portfolio.  Appendix Table A9 shows that for 5x5, 4x4, and 3x3 conditional sorts, the 
number of stocks in this portfolio increases significantly (up to 74 stocks per month), and 
our results remain robustly large and significant.   
  It is also important to note here that firms only report R&D expenses once per 
year, and we only calculate Ability once per year.  Thus, although we report monthly 
returns in this table, we only rebalance our portfolios once per year. 
We also find virtually no reversal of the abnormal returns we document here.       
Panel A of Figure 1 plots the spread portfolio (GoodR&D-BadR&D) of Cumulative 
Abnormal Returns (CARs) following portfolio formation at time 0 through the first 
eighteen months, and Panel B plots the GoodR&D portfolio.  Both equal- and value-
weighted CARs are shown, which are the size-BM-momentum-adjusted returns each 
month.  Returns of the spread (and GoodR&D) portfolios are large and significant in the 
first year (documented in Table IV), and then returns drift up slightly but basically 
                                                 
11 This 1.93% is also larger than the combined market share of the “Loser portfolio” (Decile 1) from the 
momentum anomaly (Jegadeesh and Titman (1993)), which comprises an average of 1.81% of total market 
capitalization each year, and accounts for roughly two-thirds (65%) of the profits to the (Winner-Loser) 
momentum strategy.  
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plateau.  Importantly, even continuing on into the second and third years, there is no 
reversal in returns. This suggests that we are not capturing a form of overreaction, but 
instead that the embedded information about innovation that the market is misvaluing is 
important for fundamental firm value.     
Figure 2 graphs the equal-weight yearly returns to the spread portfolio.
12  Figure 2 
shows that the annual returns to the strategy are fairly stable across time, and the 
average annual return to the spread portfolio across the 29 years in our sample is 10.8% 
(t=2.29).  In Appendix Table A2 we also split our sample into three distinct sub-periods, 
and show that no single sub-period drives our results.  For example, the value-weight L/S 
spread is 46 basis points per month (t=1.01) in the 1980s, 115 basis points per month 
(t=2.45) in the 1990s, and 142 basis points per month (t=1.85) in the 2000s; the equal-
weight equivalents are 25 basis points per month (t=0.55) in the 1980s, 121 basis points 
per month (t=3.67) in the 1990s, and 135 basis points per month (t=2.78) in the 2000s.  
Further, the annual correlation of these spread portfolio returns with the excess market 
return is low: 0.29 for the equal-weight, and 0.11 for the value-weight.
13  
In Table IV we demonstrate that simple sorts on R&D or Ability alone yield no 
pattern in average returns.  In Panel A, we present monthly portfolio returns for quintiles 
based on R&D (scaled by sales).
14  W e  g r o u p  s t o c k s  w i t h  n o  R & D  ( R & D zero) into a 
separate portfolio.
15  Panel A indicates that excess returns across the various groups are 
very similar, and that the spread in returns between R&Dhigh  and R&Dlow, and also 
between R&Dhigh and R&Dzero are small and insignificant.  We also characteristically-
adjust returns (as in Daniel et al. (1997)) using 125 value-weight size/book-to-
market/momentum benchmark portfolios.  Again we see no pattern in the abnormal 
return spreads of portfolios sorted on R&D.  Note that these results are not sensitive to 
the particular breakpoints chosen, to the particular risk-adjustment procedure employed, 
or to the particular scaling variables used (except for market equity, of course, which 
                                                 
12 The analogous value-weight version of this figure can be found in the Appendix, as Figure A1. 
13 Monthly return correlations with the monthly excess market return are even lower: 0.09 for the equal-
weight and 0.03 for the value-weight. 
14 The results are the same if we use the three-way sorts used in Table III. 
15 We separate out the R&Dzero to show any differences that may arise in this portfolio (as these make up 
roughly 25% of the firms that report R&D).  Table IV shows that these stocks do not have significantly 
different returns.  Further, including these in the interaction (or excluding them) does not materially affect 
the results (i.e., Table V actually does this comparison in Columns 3 and 4, and the results are nearly 
identical in magnitude and significance).    
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mechanically produces a scaled price effect when used as a denominator irrespective of 
numerator (see Fama and French (1996)). 
  Panel B of Table IV presents the average monthly portfolio returns associated 
with simple sorts on our ability measure.  As with the simple sorts on R&D, these sorts 
on ability yield no obvious pattern in excess returns or abnormal returns, and the spread 
between Abilityhigh  and Abilitylow is always near zero and insignificant.  Lastly, the 
correlation of R&D and Ability is -0.04.  In other words, they seem to be picking up quite 
different information about firms.
16 
  In summary, the results in Tables III and IV demonstrate that our simple 
classification scheme, which is designed to isolate high-ability firms solely based on their 
past success in converting R&D into future sales, produces a large spread in future 
abnormal returns that is not present when looking at simple sorts on R&D, or simple 
sorts on ability alone.  This finding highlights the fact that even though two firms may 
spend an equal amount on research and development, it is critical to understand the 
likely effectiveness of these expenditures, and that one can estimate this effectiveness by 
simply looking at a firm’s past experience.  Thus our approach offers an ex-ante method 
for identifying future innovation that is likely to be successful, which we show is in fact 
the case in Section III. 
    
B.  Cross-Sectional Regressions 
  Our next set of tests employ monthly Fama and Macbeth (1973) cross-sectional 
regressions each month to further assess the predictive power of our ability classification.  
To control for the well-known effects of size (Banz (1981)), book-to-market ((Rosenberg. 
Reid, and Lanstein (1985), Fama and French (1992)), and momentum (Jegadeesh and 
Titman (1993), Carhart (1997)), we include controls for these as independent variables.  
Additionally, we include controls on the right-hand side for one-month past returns (to 
capture the liquidity and microstructure effects documented by Jegadeesh (1990)), 
volume (the average daily share turnover during the previous 12 months), and return 
volatility (the standard deviation of daily returns over the previous 12 months).  Lastly, 
                                                 
16 We have also calculated the correlation of the R&Dhigh and Abilityhigh categorical variables, which is -0.25, 
again suggesting that neither heavily investing in R&D, nor having a high Ability using this measure, 
implies much about the other.  
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we include industry fixed effects to control for any industry level characteristic that may 
be driving our results.  Our variable of interest is the interaction between our measure of 
high ability (Abilityhigh) and R&D.  Analogous to Table IV, Abilityhigh is a dummy 
vsriable equal to one for stocks in the highest quintile of ability each year, and zero 
otherwise.  We include specifications with both a continuous measure of scaled R&D (i.e., 
log(1+(R&D/Sales))), as well as a categorical variable (R&Dhigh) equal to one for stocks 
above the 70th percentile in scaled R&D each year.
17  W e  h a v e  a l s o  r u n  a l l  o f  t h e  
regressions in this paper using pooled regressions with month or firm fixed effects, and 
the results are very similar to those reported here. 
  The monthly cross-sectional regression estimates in Table V confirm our earlier 
portfolio results: firms that exhibit high ability in the past and that continue to spend a 
large amount on R&D outperform in the future.  In Column 1, the coefficient on the 
variable of interest, Abilityhigh*R&Dhigh, is 0.627 (t=2.41), which is similar in magnitude to 
the portfolio return results in Table IV.  Columns 2-4 show that including controls and 
industry fixed effects has no effect on this finding.  Further, the coefficients in Column 4 
indicate that the equivalent of the spread portfolio from Table IV in these regressions 
(i.e., Abilityhigh*R&Dhigh - Abilitylow*R&Dhigh) is 99 basis points per month (78.5 — (-20.8)), 
again similar in magnitude to the Table IV spread portfolio results.  In Columns 5-8, we 
present a similar result, but this time focusing on the interaction of ability with a 
continuous measure of R&D.  Column 5 reports that the coefficient on Abilityhigh* 
log(R&D) is positive and significant (=5.433, t=2.14); to get an idea of the magnitude of 
this result, a one-standard-deviation increase in log(1+(R&D/Sales)) (=.07) implies that 
future returns are 38 basis points higher for high ability firms relative to all other firms.   
 
C.  Out-of Sample Tests: International Evidence and Pre-1980 U.S. Evidence 
To further investigate the robustness of our results, we also conduct a series of out-of-
sample tests.  In particular, we check if our main findings hold both internationally and 
in the period prior to our original sample period. We report these results in Table VI.  
This table presents monthly Fama-MacBeth (1973) regressions of returns on R&D and 
                                                 
17 The benefit of the categorical variable interaction terms is that the coefficient can be interpreted directly 
as the future abnormal return (controlling for all other variables), of the High Ability firms with large 
spending on R&D.   
Misvaluing Innovation — Page 14 
 
Ability for an international sample of stocks (UK, Japan, and Germany) and an early 
U.S. sample period (1974 to 1980).
18 For the international sample, the R&D and ability 
breakpoints are computed separately for each country. Returns, market capitalization 
figures, and prices are converted to U.S. dollars for the international sample.  We also 
include country fixed effects in the pooled international regressions of Columns 1 and 2.  
In all samples we exclude lagged low price stocks: 5th price percentile (by month) for 
international stocks, and $5 for the U.S. stocks. The sample period is July 1995 to 
December 2010 for the international sample, and July 1974 to June 1980 for the U.S. 
sample. 
Columns 1-5 of Table VI indicate that our classification of high R&D ability firms 
investing in R&D is also predictive of future returns in this international sample of 
stocks.  For example, Column 2 of Table VI reports a coefficient on R&Dhigh*abilityhigh of 
0.501 (t=2.24), which is both economically and statistically significant.  Columns 3-5 then 
show this separately for each of the three countries.  These columns indicate that our 
results are strongest for the UK, but that all three countries reveal a meaningful spread 
in magnitude; specifically, the spread (R&Dhigh*Abilityhigh - R&Dhigh*Abilitylow) is 
106 basis points (92-(-14)) per month in the UK, 37 basis points (41-4) per month in 
Japan, and 34 basis points (-14-(-48)) per month in Germany. 
Columns 5 and 6 of Table VI show that the early-period U.S. sample also delivers 
similar results.  For instance, Column 4 reports a coefficient on R&Dhigh*abilityhigh of 
0.581 (t=1.05); this estimate is statistically insignificant due to the small number of firms 
in these tests, but the magnitudes are again large and similar to those found in our 
baseline sample and in the international sample.  We choose to start the baseline sample 
in 1980 as the accounting treatment of R&D expense reporting was not standardized by 
FASB until 1974 (Financial Accounting Standards Board Statement No. 2), as also noted 
in Eberhart et al. (2004).  Given that we need at least 6 years of prior data to estimate 
ability, this places our starting date at 1980. 
  Taken as a whole, these out-of-sample results confirm the key findings from Table 
V (which uses our baseline US-sample from 1980-2008), and help to alleviate any concern 
                                                 
18 The data before 1974 (or more formally, 1968, given our six year ability classification period) are too thin 
to employ our regression-based classification scheme.  
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that our results are due to data mining.   
 
D. Controlling for Other R&D-Related Effects 
Next we examine the extent to which our findings are related to previous R&D-
related patterns that are known to exist in the cross-section of stock returns.  Specifically, 
we now directly compare our results to the findings in Eberhart et al. (2004), Daniel and 
Titman (2006), and Hirshleifer et al. (2010), and test if our results are distinct and add to 
the findings in these papers.   
To do so, we re-run our baseline regressions from Tables V and VI, and specifically 
control for the effects documented in these papers.  We present the results of these tests 
in Table VII.
19  The first four columns of Table VII illustrate the additional impact of our 
findings relative to those in Eberhart et al. (2004).  Specifically, following the approach in 
Eberhart et al. (2004), who find that large increases in R&D expenditures predict positive 
future abnormal returns, we construct variables called “∆R&D
large
t-1” and “∆R&D
large
t-5,t-1” 
designed to capture large increases in R&D that took place last year and over the past 
five years (taking an average), respectively.  As in Eberhart, et al. (2004), we identify a 
“large change” if: i) raw R&D increased by 5%; ii) the level of R&D (divided by lagged 
assets) is greater than 5%; and iii) the change in R&D (divided by lagged assets) is 
greater than 5%.  As columns 1-4 demonstrate, we find evidence consistent with the 
results reported in Eberhart et al. (2004), namely that large increases in R&D predict 
higher future returns.  However, the inclusion of these variables has no impact on our 
main result, and our result remains roughly 3 times larger in magnitude: e.g., in column 
4, the future return spread on (R&Dhigh*abilityhigh minus R&Dhigh*abilitylow) 
=0.975=(0.742-(-0.233), F-stat=10.15), while the coefficient on ∆R&D
large
t-5,t-1 (which 
shows the most predictive ability for future returns in our tests) is 0.324.  Thus we 
conclude that our results are essentially orthogonal to those in Eberhart et al. (2004).      
The last four columns of Table VIII illustrate the additional impact of our findings 
                                                 
19 In addition, when we control for the effect of R&D divided by lagged market capitalization (documented 
in Chan, Lakonishok, and Sougiannis (2001)) on future returns, our results are unchanged.  For example, 
the future return spread on (R&Dhigh*abilityhigh minus R&Dhigh*abilitylow) =0.955=(0.738-(-0.223), F-
stat=9.97) in the regressions from Table V, while the coefficient on [(R&D/MktCap)high minus 
(R&D/MktCap)low]=0.562=(0.298-(-0.264)), F-stat= 23.88.  
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relative to those in Daniel and Titman (2005), who find that the book-to-market effect is 
largely driven by overreaction to intangible information, and Hirshleifer et al. (2010), who 
show that a firm-level measure of innovative efficiency is positively related to future 
returns.  Hirshleifer et al. (2010) measure innovative efficiency as patents divided by 
lagged raw R&D.  Again we are able to replicate the findings in both of these papers in 
our sample, but find that our effect remains unchanged by their inclusion.  For example, 
in Columns 5 and 6 we observe the negative predictive effect of intangible information on 
future returns when we compute the return to tangible versus intangible information as 
in Daniel and Titman (2006), but our result is unchanged by the inclusion of this 
measure.  We also replicate the effect documented in Hirshleifer et al. (2010), but find 
that our effect is again roughly 3 times larger in magnitude: e.g., in column 8, the future 
return spread on (R&Dhigh*abilityhigh minus R&Dhigh*abilitylow ) =0.971=(0.749-(-0.222), F-
stat=10.03), while the future return spread on [(Patents/RD)high minus (Patents/RD)low ] 
=0.321=(0.032-(-0.297), F-stat=5.48).  In addition, the predictive ability of the 
Hirshleifer et al. (2010) measure appears to be coming primarily from the poor future 
performance of low patent intensity firms, whereas our effect comes primarily from (high 
ability/high R&D) firms earning high future returns.   
Collectively, these findings suggest that our approach is picking up a new and 
previously undetected pattern in the cross-section of stock returns associated with the 
market’s misvaluation of high R&D ability firms. 
 
E.  Robustness: Using a Non-Regression Based Measure of Ability 
Our final robustness check utilizes a different, non-parametric method for 
classifying R&D Ability.  Rather than using the first-stage regressions described in 
Section II in order to determine Ability, we employ simple cross-sectional sorts of scaled 
measures of output per unit of R&D.  We use both profit/lagged R&D and sales/lagged 
R&D as measures.  Here, lagged R&D represents an average of the last 1-5 years of R&D, 
to be flexible to the lead time of turning R&D into sales (and profit).  This alternate, 
non-parametric approach is meant to address any potential concerns that our regression 
framework may introduce into how the Ability coefficients are determined.  Appendix 
Table A6 shows that the equal-weight (value-weight) excess returns on the spread  
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portfolio derived from sorts on sales/lagged R&D–the analog of the excess return rows in 
both panels in Table III--is 103 basis points per month, t=2.28 (83 basis points per 
month, t=1.46). 
 
III. Mechanism 
  In this section, we provide a series of additional tests aimed at isolating the 
mechanism driving our main result.  In particular, we examine several implications of our 
results, and also try to pinpoint why the market does not recognize the information in 
past R&D track records.   
 
A. Real Outcomes: Patents and Products 
First we explore real outcomes associated with our high ability firms.  The goal 
here is to assess if the firms that we classify as high ability and that invest heavily in 
R&D, which we saw in Section III experience high future returns, also produce tangible 
results with their research and development efforts.  An alternative explanation for our 
results thus far is that the firms that we classify as high ability firms may simply 
anticipate higher sales growth in the future, and hence may ramp up R&D and other 
firm-level activities in advance of sales growth; therefore the high first-stage correlation 
between R&D and future sales growth that defines our high ability firms may not be due 
to actual skill at conducting R&D, but rather skill at predicting future sales growth.  To 
begin to rule out this alternative story, we first explore whether R&D spending by high 
ability firms leads to tangible outcomes, in the form of additional patents (and patent 
citations) in the future, as well as additional new products in the future.   
To examine the real effects of firm-level R&D, we explore patents and patent 
citations using data from the NBER’s U.S. Patent Citations Data File (when matching to 
our data, this gives a sample of 1980-2006).  The idea behind exploring patents is that 
they represent a successful outcome measure of past research and development efforts.  
Patents enable firms to maintain a competitive advantage for a lasting period of time, 
and as such are intrinsically valuable from a firm’s point of view.  We analyze both the 
number of patents (using both the stock and annual flow of firm-level patents), and the  
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number of patent citations (again using a stock and flow-based measure).
20  Following 
Hall, Jaffe, and Trajtenberg (2001), using patent citations enables one to create indicators 
of the "importance" of individual patents.  Our approach is motivated by a vast 
literature (see, for example, Griliches (1981), Griliches (1984), Pakes (1985), Jaffe (1986), 
Griliches, Pakes, and Hall (1987), Connolly and Hirschey (1988), Griliches, Hall, and 
Pakes (1991), Hall (1993a), Hall (1993b), and Hall, Jaffee, and Trajtenberg (2005)) 
showing that patents, and particularly patent citations, are viable measures of R&D 
“success.” 
  Table VIII presents annual Fama-MacBeth cross-sectional regressions of future 
(log) patents and (log) patent citations on past R&D ability. All these dependent 
variables are measured relative to the application year of the patent (rather than the 
grant year). Specifically, our explanatory variable of interest is again the interaction 
between our measure of high ability (Abilityhigh) and R&D.  Analogous to Table IV, 
Abilityhigh is a categorical vsriable equal to one for stocks in the highest quintile of ability 
each year, and zero otherwise.  For R&D, we include specifications with continuous 
measures of one- and five-year averages of past R&D (i.e., log(1+(R&D/Sales))-1 and 
log(1+(R&D/Sales))-5,-1.
21  We also include lagged control variables for size (log(MEt-1)), 
book-to-market ratio (log (BEt-1/MEt-1)), leverage (log(1+(Dt-1/BEt-1)), institutional 
ownership, and firm age (measured in years since a firm’s first appearance on CRSP).  
We also include industry fixed effects (in each annual regression of the Fama-MacBeth 
framework) where indicated. 
  Column 1 of Table VIII reveals a positive and significant coefficient (=11.96, 
t=7.20) on the interaction term (Abilityhigh * log(1+(R&D/Sales))), indicating that firms 
with high past ability that continue to do R&D produce more patents in the future than 
other firms.  To get a sense of the magnitude of this effect, a one-standard deviation 
move in R&D by a high ability firm leads to an additional 0.84 patents in the stock of 
patents for that firm (the median firm’s stock of patents is 2.56, so this represents an 
increase of 33%).  In column 2 of Table VI, using the stock of patent citations as the 
                                                 
20 Citations are calculated using the HJT procedure described in Hall et al. (2001). 
21 We have also tried using a categorical variable (R&Dhigh) equal to one for stocks above the 70th 
percentile in R&D each year, in place of these continuous measures of R&D, and the results are similar to 
those presented here in magnitude and significance.  
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dependent variable, we find that firms with high past ability that continue to do R&D 
also receive significantly more citations on their patents. Again the magnitude of this 
result is large: a one-standard deviation increase in R&D by a high ability firm leads to 
an additional 1.17 citations in the stock of patent citations for that firm (the median 
firm’s stock of citations is 5.02, so this represents an increase of over 23%).
22 
  Columns 3 and 4 present similar results, but this time using the annual flow of 
firm-level patents and patent citations, as opposed to the stock variables.  High ability 
firms that continue to do R&D produce more patents per year (=9.07, t=7.10) and 
receive more patent citations per year (=14.87, t=6.80) than other firms.  The 
corresponding magnitudes are again large; a one-standard deviation increase in R&D by a 
high ability firm translates into 0.63 more patents per year (a 58% increase) and 1.04 
more patent citations per year (a 52% increase).  And as Table VIII shows, including 
additional control variables, adding industry fixed effects, or using five-year averages of 
past R&D in Panel B (in place of last year’s R&D) makes no difference to these results.     
  Table IX presents another test of the real, direct impact of R&D by exploring the 
impact of high ability firms’ R&D efforts on the development of new firm-level products.  
We use the segment-level Product Database from the Compustat Segment File to 
compute the number of products per year for each firm; we exclude geographic and 
operating segment breakdowns, and focus on business segment breakdowns in order to 
capture true firm-level product innovations.  The Compustat Segment file records a 
unique product number for each new product and carries that product number through 
time (e.g., iPod is product number 10 for Apple, starting in 2004), and is available from 
2000-2008; by computing the maximum product number in each year, we can get a sense 
of how many products a firm has produced at any given point in time (this is analogous 
to the patent stock measure used in Table VIII).  In our tests, we report specifications 
using this maximum product number as our outcome measure, but we have analyzed a 
variety of different measures of product-level innovation, such as the total number of 
products listed in a given year, the change in the number of total products listed in a 
                                                 
22 We have also run the regressions in Table VIII controlling for past lagged values of patents and citations 
(essentially first-differencing).  The magnitudes of the effects are similar (and remain statistically 
significant), implying roughly 70-95% increases in patents and citations for high ability firms that have a 
one standard deviation increase in R&D expenditures.  
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given year, etc., and the results are similar to those presented here. 
  Table IX presents the results of annual Fama-Macbeth cross-sectional regressions 
of our firm-level (log) product measure on the interaction of high ability and level of 
R&D (constructed exactly as in Table VIII).  We control for the average of each firm’s 
maximum product number over the past five years on the right-hand side of these 
regressions, and include the same control variables and fixed effects as in Table VIII.   
  The estimates in Table IX indicate that high ability firms’ continuing R&D efforts 
are positively related to the development of new firm-level products.  In column 1, the 
positive and significant coefficient (=4.41, t=2.74) on the interaction term (Abilityhigh * 
log(R&D)) implies a 20% increase in the number of additional products for a one-
standard deviation increase in R&D by a high ability firm.  Including additional control 
variables, adding industry fixed effects, or using five-year averages of past R&D (in place 
of last year’s R&D) again makes no difference to these results.     
  Taken together, the findings in Tables VIII and IX suggest that high ability firms 
are not simply ramping up R&D in advance of higher-than-average sales growth, as an 
anticipation story would suggest.  Instead, the firms we identify as high-ability firms 
appear to be investing in research and development activities that yield tangible, 
successful outcomes in the form of increased numbers of patents, patent citations, and 
new product innovations. 
 
B. Heterogeneity in Information Provision by Firms 
Next we analyze the information environment of firms, in order to test the 
hypothesis that information opacity may help explain why the market fails to properly 
understand the information embedded in firms’ past track records.  Under the assumption 
that firms that provide more earnings guidance are also likely to provide more 
information to investors more generally (as in Jones (2007)), we explore the impact of 
managerial guidance on our key result.  If firm opacity is impacting whether investors are 
able to decipher firm ability, then more open firms should have less of the return 
predictability that we document.  Specifically, we test if the returns are lower for high 
ability firms who provide more earnings guidance relative to high ability firms who 
provide less earnings guidance.  We find precisely this pattern in the data: in Panel A of  
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Table X, we show that the triple interaction of (R&Dhigh*abilityhigh*Guidancehigh) is 
strongly negative and but not quite significant in our main regression specification, 
indicating that information asymmetry is may be related to the return predictability we 
observe.    
 
C. Founder Effects 
On the issue of what drives persistence in R&D skill within a given firm over time, 
one plausible hypothesis is that some firms (e.g., Apple) may have had the benefit of a 
unique “founder effect,” which could persist for many years but then diminish after the 
founder leaves.  Under this story, founder-led firms might tend to underperform after 
their founder leaves the firm.  We test this idea directly by comparing non-founder-led 
firms to founder-led firms, and find marginally significant evidence that high-ability 
founder-led firms have larger impacts on future returns than non-founder-led firms. 
Specifically, Table X Panel B shows that the marginal effect of having a founder is 
almost 3 times the main effect; we view this result as suggestive evidence of founder 
effects in firm-level R&D ability.
23 
 
D. Variation in Financial Constraints 
  Continuing on the issue of interpretation, we next exploit variation in firm-level 
financial constraints, with the idea that financially constrained firms will likely only be 
able to increase R&D when they have exceptionally good R&D projects to invest in.  
Hence, those firms that are limited in their ability to raise financing would be hesitant to 
waste resources on R&D and to simply ramp up all spending in anticipation of perceived 
growth.  Therefore, even amongst those firms that have high ability at R&D, comparing 
a financially constrained firm and an unconstrained firm, we may expect a stronger signal 
from the R&D spending of the financially constrained firm.   
We test this notion in Panel C of Table X when we interact our measure of 
GoodR&D (R&Dhigh * Abilityhigh) with the Kaplan and Zingales (1997) “KZ-index” of 
                                                 
23 We also tried to exploit within-firm variation in firms before and after a founder leaves to identify the 
impact of a founder at a firm-specific level, but we did not have enough power to detect any meaningful 
effects given the tiny number of observations available for this additional test.  
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financial constraints, and re-run our basic return predictability regression test from Table 
IV.  Specifically we form dummy variables of the KZ-index based on the same Fama and 
French (1996) 30/40/30 breakpoints across all firms each month.  We then interact these 
three dummy variables with our GoodR&D measure.  We examine the return 
predictability of GoodR&D firms within these three categories of financial constraints 
(GoodR&D*KZhigh, GoodR&D*KZlow, GoodR&D*KZmid) in Table X.  Panel C indicates 
that our result is indeed strongest among firms that are financially constrained 
(=1.865=(0.450+1.415), t-stat=2.27).  Similarly, using financial constraints measured by 
cash balances of the firm provides the same intuition (highest coefficient for most 
constrained (lowest cash) firms =1.159=(0.732+0.427), t-stat=1.50). 
 
E. What Happens to Firms that Ramp Up All Operations? 
  We run a final test to pinpoint the mechanism behind our results by examining 
the future returns of high past R&D ability (Abilityhigh) firms that continue to ramp up 
all firm operations.  The idea behind this test is to specifically rule out the alternative 
explanation that our interaction measure simply picks up firms that are: i.) good at 
predicting their future growth (through Abilityhigh), ii.) ramping up all firm operations, 
including R&D (through R&Dhigh).  Instead, of course, we would like to pinpoint 
specifically the impact of firms with specific ability at R&D, translating high R&D 
expenditures into future value for the firm.  We test this by taking those firms who we 
identify as having high ability at R&D, and seeing what happens when they ramp up all 
other types of spending.  For example, we look at large increases in capital expenditures 
(CAPEXhigh) and large increases in total operating expenditures (OPEXhigh) by these 
firms, rather than just large increases in R&D (as in Tables III-V).   
Again, if the high future returns we observe are a consequence of firms simply 
ramping up all expenditures in advance of future sales, then the interaction of our ability 
measure with any type of expenditure should predict high returns.  We test this in Panels 
E and F of Table X, where we replicate our Table V regressions, but include interactions 
with high ability and high spending on capital expenditures (CAPEXhigh), or high total 
expenses (OPEXhigh), in place of high spending on R&D (R&Dhigh).  Panels E and F 
indicate that both interaction terms (both in Column 1 of the respective panels) are near  
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zero and insignificant, in contrast to the strong positive predictive power of GoodR&D 
(R&Dhigh * Abilityhigh) documented earlier.   
Collectively, the findings in Table X reinforce the idea that our empirical approach 
isolates a set of firms with predictable, persistent R&D skill, and not simply a set of firms 
with skill at predicting future firm growth.  We also find suggestive evidence that R&D 
skill is positively related to the presence of a founder.  Lastly, we show that the market’s 
failure to understand the implications of R&D track records is related to heterogeneity in 
information provision by firms. 
 
IV. Discussion 
In this section, we discuss two important aspects of our methodology.  The first 
has to do with the determinants (and optimality) of firm-level R&D.  We are agnostic in 
the paper as to what drives the variation between firms in the level of their R&D 
investment.  In other words, one could make the argument that all firms should be 
individually solving for the optimal level of R&D expenditure.  Given their (privately 
known) ability at research and development, a firm will continue R&D expenditures until 
the value of the marginal dollar of R&D is equal to its opportunity cost.  If each firm 
does this, then we simply observe (through R&D expenditures) the optimal amount of 
research that each firm is undertaking.  On the other hand, perhaps because of financial 
constraints, other frictions, or even errors in firm decision-making, firms may have sub-
optimal levels of research expenditures.  However, whether the amount of R&D is optimal 
or not, the market should still be expected to value the firm’s chosen R&D level.    
This brings up a second important aspect of our findings.  Namely, in either case 
above (optimal investment or not), as long as the market correctly extracts the 
information about a given firm’s level of R&D along with its R&D ability, there should 
be no predictability.  More generally, even if the market is always incorrect about the 
effect of R&D on future value for every firm, there would still be no implied return 
predictability, as the market would sometimes overvalue, and sometime undervalue, the 
impact of R&D on future firm value.  Only in the case that the market is consistently 
incorrect in an ex-ante identifiable and predictable manner, would the market’s 
misvaluation of innovation translate into return predictability.  This is, in fact, precisely  
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what we show is happening across the universe of firms and innovation expenditures 
undertaken.  Collectively, the results of the paper suggest that the market fails to 
incorporate the information in past successes when evaluating the likely efficacy of 
today’s investments.  In doing so, we provide evidence of a new friction in the response of 
capital to trading opportunities. 
 
V. Conclusion 
In this paper we demonstrate that firm-level innovation is predictable, persistent, 
and relatively simple to compute, and yet the stock market ignores the implications of 
publicly available information when setting prices.  Our approach is based on the simple 
idea that some firms are likely to be skilled at certain activities, and some are not, and 
this skill may be persistent over time.  Hence, past track records associated with a given 
activity represent a straightforward way to gauge the future prospects of firms.  Using 
this idea as the starting point for our analysis, we examine the predictability of firm-level 
R&D track records for future returns and future real outcomes.  We show that despite 
the uncertainty typically associated with R&D investment, substantial return 
predictability exists by exploiting the information in these firm-level track records.  We 
find that a long-short portfolio strategy that takes advantage of the information in past 
track records yields abnormal returns of 11 percent per annum.  In doing so, we add to a 
growing literature showing that the market appears to underreact to the information 
contained in R&D investments.  Our tests pinpoint a specific channel through which the 
market under-reacts to firm-level R&D investments by highlighting the importance of the 
interaction between a successful past track record and current R&D activity.   
We show that the firms we classify as high ability based on their past track 
records also produce tangible results with their research and development efforts.  In 
particular, R&D spending by high ability firms leads to increased numbers of patents, 
patent citations, and new product innovations by these firms in the future.  The same 
level of R&D investment by low ability firms does not.  Additionally, we document that 
high R&D ability firms that continue to spend substantial amounts on other activities, 
such as capital expenditures or total expenses as opposed to R&D, do not experience high 
future returns.  These results suggest that our findings are unlikely to be driven by firms  
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that simply anticipate higher sales growth in the future, and hence ramp up R&D and 
other firm-level activities in advance of sales growth.  Rather, our findings are consistent 
with the idea that the firms we define as high ability are in fact truly skilled at R&D, 
and that future firm-level innovation by these firms is unanticipated by the market. 
Given the substantial shift in the funding of research and development from the 
public sector to the private sector over the past few decades, the extent to which the 
stock market properly values investments in R&D is increasingly important.  Our 
findings suggest that while R&D investment is indeed associated with considerable 
uncertainty, it is possible to identify potential winners and losers solely based on publicly 
available information.  The fact that the stock market fails to adequately incorporate this 
type of information raises important questions about the efficiency of R&D investment in 
the economy.  
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Returns to Correctly Valuing Innovation, Event-time Abnormal Returns
This ﬁgure shows the size-B/M-mom adjusted cumulative abnormal returns to portfolios that follow high
Ability/high R&D and low Ability/high R&D ﬁrms in the 18 months following formation. Each month
stocks with positive lagged R&D and non-missing lagged Ability are double sorted into portfolios using
quintiles for Ability and 30%/40%/30% breakpoints for R&D. The R&D (Ability estimate) used to form
the portfolios is the R&D (Ability estimate) from the ﬁscal year ending in calendar year t-1 from July to
December and calendar year t-2 from January to June (as in Fama and French (1993)). R&D is scaled by
sales. Ability is computed as described in Table II. The high Ability/high R&D (low Ability/high R%D)
portfolio is formed from the intersection of the top 20% (bottom 20%) of ability and top 30% of R&D. The
top graph shows the abnormal return spread between high Ability/high R&D and low Ability/high R&D
portfolios. The bottom graph shows the abnormal return on the high Ability/high R&D portfolio. abnormal
returns are computed by adjusting returns using 125 size/book-to-market/momentum portfolios (formed as
in DGTW (1997)). The sample period is July 1980 to December 2009.
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Annual Returns to Equal-Weight Ability/R&D Spread Portfolio
This ﬁgure shows annual returns to high Ability/high R&D minus low Ability/High R&D
spread portfolios. Each month stocks with positive lagged R&D and non-missing lagged
Ability are sorted into quintiles for Ability and 30%/40%/30% breakpoints for R&D. Port-
folios are formed every month from the intersection of these two sorts. The R&D (Ability
estimate) used to form the portfolios is the R&D (Ability estimate) from the ﬁscal year end-
ing in calendar year t-1 from July to December and calendar year t-2 from January to June
(as in Fama and French (1993)). R&D is scaled by sales. Ability is computed as described in
Table II. The high Ability/high R&D (low Ability/high R&D) portfolio is formed from the
intersection of the top 20% (bottom 20%) of ability and top 30% of R&D. The ﬁgure also
show the annual excess return on a proxy for the market portfolio (VW portfolio of CRSP
common stocks), and recession periods (as deﬁned by the NBER) are denoted by the gray
shaded areas.
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ρ(rspread,rM) = 0.29
Spread Return
rM-rfTable I
Summary Statistics: R&D-Ability Sample Compared to CRSP Stocks
This table compares the R&D-Ability sample of stocks with a sample of all CRSP common
stocks. The R&D-Ability sample is comprised of CRSP common stocks, and non-missing
R&D Ability estimates. Ability is computed as described in Table II. R&D is scaled by sales.
Each year in July the percentile ranks of market-cap, B/M, leverage, r 12; 2, volatility, and
turnover for every stock are computed. The table reports pooled summary statistics of
the percentile ranks. Market-cap is the market capitalization of the ﬁrm from the end of
June. B/M is book equity to market equity and is computed as in Fama and French (1993).
Leverage is long term debt divided by book equity where book equity is computed as in
Fama and French (1993). Both B/M and leverage are from the ﬁscal year that ended in
calendar year t   1. r 12; 2 is the return from month t   12 (previous July) to t   2 (May).
Volatility is the standard deviation of daily returns computed over the past year (250 trading
days). Turnover is average daily share turnover during the last year (250 trading days). The
sample period is 1980 to 2009.
Panel A: All CRSP Common Stocks
Breakpoints Mean Median St. Dev
Percentile Market-Cap NYSE 0.22 0.10 0.27
Percentile B/M NYSE 0.47 0.46 0.31
Percentile Leverage NYSE 0.38 0.31 0.32
Percentile r 12; 2 All 0.50 0.50 0.29
Percentile Volatility All 0.50 0.50 0.29
Percentile Turnover All 0.50 0.50 0.29
Panel B: R&D/Ability Sample
Breakpoints Mean Median St. Dev
Percentile Market-Cap NYSE 0.31 0.17 0.32
Percentile B/M NYSE 0.43 0.39 0.30
Percentile Leverage NYSE 0.32 0.24 0.28
Percentile r 12; 2 All 0.52 0.52 0.28
Percentile Volatility All 0.49 0.49 0.27
Percentile Turnover All 0.56 0.57 0.27Table II
R&D Ability Summary Statistics and Persistence in Ability
Panel A reports pooled summary statistics for Ability, R&D (scaled by sales), and sales
growth. R&D ability is computed for each ﬁrm every year using ﬁve (j = 1:::5) time series
regressions of sales growth on past R&D:
log(
Salesit
Salesit 1
) = 0 + jlog(1 + R&Dit j) + it:
A back window of 6-8 years of non-missing data is required. An additional requirement is
that at least half of the R&D observations are non-zero. Ability is computed as the average
of the ﬁve slope coeﬃcients (j). Panel B reports the fraction of stocks that are in ability
quintile x in year t given they are in ability quintile x in year t   lag. Speciﬁcally, panel B
reports means of the time series of these fractions for each quintile. The sample period is
1980 to 2009.
Panel A: Ability Summary Statistics
Mean Median St. Dev
Ability 3.26 3.29 11.11
log(1 + R&D) 0.18 0.17 0.07
log(salest=salest 1) 0.07 0.07 0.28
Panel B: Mean Annual Persistence in Ability
Prob(Quintile = i), year = t if Quintile = i, year = t   lag
Ability Quintiles
Lag Low 2 3 4 High
1 0.66 0.50 0.51 0.49 0.70
2 0.48 0.37 0.40 0.36 0.55
3 0.38 0.32 0.35 0.29 0.46
4 0.30 0.30 0.32 0.26 0.39
5 0.26 0.28 0.30 0.24 0.36Table III
Double Sorts on R&D and Ability: Monthly Portfolio Returns
This table presents monthly portfolio returns (in %) for double sorts on Ability and R&D. Each
month stocks with positive lagged R&D and non-missing lagged Ability are sorted into quintiles
for Ability and 30%/40%/30% breakpoints for R&D. Portfolios are formed every month from the
intersection of these two sorts. The R&D (Ability estimate) used to form the portfolios is the
R&D (Ability estimate) from the ﬁscal year ending in calendar year t-1 from July to December
and calendar year t-2 from January to June (as in Fama and French (1993)). R&D is scaled by
sales. Ability is computed as described in table II. Characteristic abnormal returns are computed
by adjusting returns using 125 (5x5x5) size/book-to-market/momentum portfolios (computed as in
DGTW (1997)), 25 size/book-to-market portfolios (computed as in Fama and French (1993)), and
17 industry portfolios (as in Fama and French (1997)). The benchmark portfolios’ weighting match
the weighting of the R&D/Ability portfolios. All portfolios (including the benchmark portfolios)
also contain the restriction that lagged price must be greater than $5 (breakpoints are computed
before imposing the lagged price restriction). Average abnormal returns are also computed using
the three factor model (Fama and French (1993)) and four factor model (Carhart (1997)).
ri   rf = i + b(rM   rf) + sSMB + hHMB + ei
ri   rf = i + b(rM   rf) + sSMB + hHMB + uUMD + ei
The sample period is July 1980 to December 2009.
Panel A: Equal-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.81 0.75 0.62 0.80 0.83 1.35 0.73
T-stat 3.04 2.61 1.48 3.00 2.81 2.76 2.61
Size-B/M-Mom Adjusted Returns
Mean -0.07 -0.04 -0.10 -0.03 0.08 0.79 0.89
T-stat -0.86 -0.43 -0.50 -0.42 0.90 2.84 3.32
Size-B/M Adjusted Returns
Mean 0.02 0.08 -0.04 0.04 0.15 0.88 0.92
T-stat 0.27 0.94 -0.18 0.57 1.79 2.84 3.33
Industry Adjusted Returns
Mean 0.15 0.12 -0.03 0.18 0.22 0.81 0.84
T-stat 1.35 1.05 -0.16 1.58 2.17 2.97 3.03
Three Factor Model 
 0.04 0.02 -0.02 0.02 0.14 0.72 0.74
T-stat 0.38 0.21 -0.09 0.20 1.45 2.52 2.59
Four Factor Model 
 0.10 0.10 0.14 0.12 0.25 0.90 0.76
T-stat 0.88 0.90 0.75 1.18 2.51 3.11 2.59Panel B: Value-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.73 0.60 0.32 0.56 0.72 1.22 0.90
T-stat 2.79 2.18 0.81 2.18 2.25 2.61 2.30
Size-B/M-Mom Adjusted Returns
Mean 0.16 -0.05 -0.20 -0.06 0.21 0.72 0.92
T-stat 1.52 -0.40 -0.91 -0.63 1.67 2.30 2.64
Size-B/M Adjusted Returns
Mean 0.11 -0.02 -0.10 0.02 0.16 0.68 0.78
T-stat 0.84 -0.13 -0.41 0.16 1.06 1.99 2.10
Industry Adjusted Returns
Mean 0.16 0.01 -0.32 0.04 0.17 0.63 0.95
T-stat 1.43 0.07 -1.48 0.42 1.52 2.02 2.61
Three Factor Model 
 0.19 -0.04 -0.16 -0.01 0.12 0.89 1.05
T-stat 1.36 -0.26 -0.62 -0.04 0.87 2.64 2.64
Four Factor Model 
 0.14 0.06 -0.15 0.01 0.19 0.78 0.93
T-stat 0.95 0.35 -0.56 0.09 1.33 2.27 2.30
Panel C: Equal Weight Portfolios Four Factor Loadings
Low Ability High Ability
R&Dlow 2 R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
b 0.99 1.00 1.11 0.99 1.01 1.18 0.06
t(b) 38.52 40.16 24.86 40.82 43.82 17.25 0.93
s 0.42 0.57 0.89 0.40 0.59 0.91 0.01
t(s) 11.95 16.88 14.63 11.92 18.61 9.75 0.15
h 0.43 0.23 -0.37 0.42 0.09 -0.51 -0.13
t(h) 11.30 6.25 -5.58 11.65 2.48 -4.98 -1.30
u -0.06 -0.08 -0.17 -0.10 -0.11 -0.18 -0.02
t(y) -2.46 -3.41 -4.18 -4.81 -5.16 -3.03 -0.29
# Stocks 84 69 25 114 60 10Table IV
Monthly R&D and Ability Portfolio Returns
This table presents monthly portfolio returns (in %) for sorts on Ability and R&D. Ability is
computed as described in Table II. R&D is scaled by sales. In panel A we form R&D quintiles. The
R&D used to form the portfolios is R&D for the ﬁscal year ending in calendar year t 1 from July
to December and calendar year t 2 from January to June (as in Fama and French (1993)). In panel
B we form Ability quintiles. The Ability used to form the portfolios is the Ability estimate from the
ﬁscal year ending in calendar year t 1 from July to December and calendar year t 2 from January
to June. Characteristic abnormal returns are computed by adjusting returns using 125 value-weight
size/book-to-market/momentum portfolios (formed as in DGTW (1997)). All portfolios (including
the benchmark portfolios) also contain the restriction that lagged price must be greater than $5.
The sample period is July 1980 to December 2009.
Panel A: R&D Portfolios
R&Dzero R&Dlow 2 3 4 R&Dhigh High   Zero
Equal-Weight: Excess Returns
Mean 0.63 0.70 0.67 0.83 0.79 0.29 -0.33
T-stat 2.11 2.56 2.36 2.35 1.82 0.58 -0.90
Equal-Weight: Size-B/M-Mom adjusted returns
Mean -0.18 -0.11 -0.07 0.15 0.24 -0.09 0.09
T-stat -1.63 -1.56 -1.03 1.71 1.66 -0.41 0.31
Value-Weight: Excess Returns
Mean 0.72 0.59 0.51 0.61 0.64 0.47 -0.25
T-stat 2.41 2.47 1.92 2.16 1.97 1.01 -0.62
Value-Weight: Size-B/M-Mom adjusted returns
Mean 0.13 0.02 -0.04 0.15 0.10 0.15 0.01
T-stat 1.00 0.27 -0.55 2.14 1.04 0.72 0.05
Number of Stocks
Mean 278 308 296 278 268 198
Panel B: Value-Weight Ability Portfolios
Abilitylow 2 3 4 Abilityhigh High   Low
Equal-Weight: Excess Returns
Mean 0.77 0.77 0.81 0.86 0.83 0.07
T-stat 2.77 2.39 2.25 2.76 3.02 1.09
Equal-Weight: Size-B/M-Mom adjusted returns
Mean -0.06 0.09 0.17 0.13 0.03 0.09
T-stat -0.87 1.03 1.39 1.56 0.60 1.50
Value-Weight: Excess Returns
Mean 0.63 0.58 0.62 0.59 0.58 -0.04
T-stat 2.59 2.11 2.13 2.12 2.22 -0.34
Value-Weight: Size-B/M-Mom adjusted returns
Mean 0.06 0.06 0.05 0.12 0.04 -0.03
T-stat 0.99 0.70 0.50 1.49 0.52 -0.31
Number of Stocks
Mean 188 170 155 174 194Table V
Fama-MacBeth Regressions of Monthly Returns on R&D and Ability
This table presents monthly Fama-MacBeth (1973) regressions of returns on R&D and Ability. The R&D
(Ability estimate) used in the regression is the R&D (Ability estimate) from the ﬁscal year ending in calendar
year t   1 from July to December and calendar year t   2 from January to June (as in Fama and French
(1993)). Ability is computed as described in Table II. abilityhigh (abilitylow) equals one if a stock is in the
top (bottom) quintile for a given month. R&Dhigh (R&Dlow) equals one for a stock if its ability estimate
is greater than the 70th (not greater than the 30th) percentile in a given month. R&Dzero equals one if
R&D = 0. log(ME) is the log of month t 1 market-cap, and log(B=M) is log book to market deﬁned and
lagged as in Fama and French (1993). r 12; 2 is the return from month t 12 to month t 2. r 1 is the one
month lagged return. turnover is average daily share turnover (100) over the past year.  is the standard
deviation of daily returns over the past year. Some regressions includes industry dummies (using Fama and
French’s (1997) 17-industry classiﬁcation scheme). The regressions only include stocks with lagged price
greater than 5. The sample period is July 1980 to December 2009. T-statistics are in parenthesis.
(1) (2) (3) (4) (5) (6) (7) (8)
R&Dhigh  abilityhigh 0.627 0.649 0.758 0.785
(2.41) (2.46) (2.86) (3.04)
R&Dhigh  abilitylow -0.140 -0.214 -0.208
(-0.77) (-1.17) (-1.15)
log(1 + R&D)  abilityhigh 5.433 5.786 9.547
(2.14) (2.25) (3.62)
log(1 + R&D)  abilitylow 0.881 0.809 -0.038
(0.52) (0.50) (-32.00)
abilityhigh -0.048 -0.103 -0.055 -0.016 -0.142 -0.213 -0.267 0.027
(-0.83) (-1.44) (-0.95) (-0.27) (-1.48) (-1.83) (-2.92) (51.02)
abilitylow -0.143 -0.101 -0.070 0.881 0.809 -0.038
(-1.90) (-1.62) (-1.11) (0.52) (0.50) (-32.00)
R&Dhigh 0.109 0.093 0.134 0.094
(0.64) (0.56) (1.13) (0.82)
R&Dlow -0.170 -0.176
(-2.38) (-2.50)
R&Dzero -0.861 -1.040
(-2.39) (-2.85)
log(1 + R&D) 0.803 0.479 1.267 0.012
(0.91) (0.53) (1.39) (11.49)
log(ME) -0.028 -0.026 -0.041 -0.049 -0.026 -0.025 -0.035 0.000
(-0.73) (-0.69) (-1.19) (-1.38) (-0.69) (-0.66) (-1.01) (15.76)
log(B=M) 0.247 0.257 0.220 0.277 0.258 0.263 0.230 -0.001
(3.55) (3.75) (3.58) (4.85) (3.62) (3.83) (3.74) (-12.85)
r 12;2 0.775 0.766 0.788 0.749 0.811 0.796 0.803 0.000
(3.59) (3.57) (4.02) (3.93) (3.63) (3.62) (4.06) (0.64)
r 1 -3.771 -4.046 -3.810 0.000
(-8.42) (-9.24) (-8.40) (1.47)
turnover -0.308 -0.320 -0.318 0.001
(-1.71) (-1.85) (-1.79) (12.92)
 -0.123 -0.114 -0.111 0.001
(-1.87) (-1.79) (-1.65) (13.28)
Industry Fixed Eﬀects Yes Yes
Number of Months 354 354 354 354 354 354 354 354
Total Observations 290272 290272 283031 283031 290272 290272 283031 283031Table VI
Fama-MacBeth Return Regressions: International and Early U.S. Sample
This table presents monthly Fama-MacBeth (1973) regressions of returns on R&D and Ability for an inter-
national sample of stocks (UK, Japan, and Germany) and an early U.S. sample period (July 1974 to June
1980). The R&D (Ability estimate) used in the regression is the R&D (Ability estimate) from the ﬁscal year
ending in calendar year t   1 from July to December and calendar year t   2 from January to June. Ability
is computed as described in Table II. abilityhigh (abilitylow) equals one if a stock is in the top (bottom)
quartile for a given month . R&Dhigh (R&Dlow) equals one for a stock if its ability estimate is in the top
(bottom) quartile in a given month. R&Dzero equals one if R&D = 0. For the international sample, the
R&D and ability breakpoints are computed separately for each country. log(ME) is the log of month t   1
market-cap, and log(B=M) is log book to market deﬁned and lagged as in Fama and French (1993). r 12; 2
is the return from month t   12 to month t   2. r 1 is the one month lagged return.  is the standard
deviation of daily returns over the past year. turnover is average daily share turnover (100) over the past
year. Returns, market-caps, and prices are converted to U.S. dollars for the international sample. We include
country ﬁxed eﬀects in the international regressions. In both samples we exclude lagged low price stocks:
5th price percentile (by month) for international stocks, and for $5 the U.S. stocks. The sample period
is July 1995 to December 2010 for the international sample and July 1974 to June 1980 the U.S. sample.
T-statistics are in parenthesis.
ALL: UK, JPN,Ger UK JPN Ger Early U.S.: 74-80
(1) (2) (3) (4) (5) (6) (7)
R&Dhigh  abilityhigh 0.510 0.501 0.923 0.416 -0.138 0.572 0.661
(2.32) (2.24) (1.37) (1.69) (-0.20) (1.04) (1.18)
R&Dhigh  abilitylow -0.158 -0.139 0.043 -0.477 0.103
(-0.84) (-0.25) (0.19) (-0.60) (0.15)
abilityhigh -0.045 -0.064 -0.085 -0.099 0.634 -0.029 -0.077
(-0.70) (-0.85) (-0.47) (-1.18) (2.03) (-0.16) (-0.37)
abilitylow -0.099 0.111 -0.187 0.379 -0.100
(-1.18) (0.63) (-1.97) (1.11) (-0.50)
R&Dhigh 0.199 0.145 0.339 0.045 0.468 0.073 0.029
(1.94) (1.39) (1.39) (0.43) (1.13) (0.32) (0.12)
R&Dlow -0.156 0.113 -0.247 -0.342 0.192
(-1.48) (0.63) (-2.04) (-1.14) (0.87)
R&Dzero -0.230 -0.199 -0.331 -0.686 0.162
(-0.73) (-0.52) (-0.84) (-0.86) (0.22)
log(ME) 0.016 0.012 0.004 0.002 -0.086 -0.214 -0.215
(0.34) (0.27) (0.07) (0.03) (-1.17) (-2.13) (-2.16)
log(B=M) 0.251 0.265 0.203 0.318 0.028 0.535 0.512
(3.09) (3.31) (1.70) (2.80) (0.14) (1.91) (1.81)
r 12;2 0.001 0.001 0.008 -0.007 0.010 0.892 0.895
(0.30) (0.24) (2.07) (-1.52) (1.40) (1.51) (1.53)
r 1 -0.048 -0.048 -0.026 -0.064 -0.004 -8.207 -8.139
(-5.77) (-5.80) (-2.37) (-6.41) (-0.22) (-5.84) (-5.94)
Country Fixed Eﬀects Yes Yes
Number of Months 186 186 186 186 126 73 73
Total Observations 185697 185697 33543 132019 17992 23601 23601Table VII
Fama-MacBeth Return Regressions: Controlling for Other R&D Eﬀects
This table presents monthly Fama-MacBeth (1973) return regressions. The R&D (Ability estimate) is the
from the ﬁscal year ending in calendar year t 1 from July to December and calendar year t 2 from January
to June. Ability is computed as in Table II. abilityhigh (abilitylow) equals one if a stock is in the top (bottom)
quintile for a given month. R&Dhigh (R&Dlow) equals one for a stock if its ability estimate is greater than the
70th ( the 30th) percentile in a given month. R&Dzero equals one if R&D = 0. R&D
large
t 1 (R&D
large
t 5;t 1)
refers to large increases in R&D over the past year (past ﬁve years) where the follow conditions deﬁne a large
increase: raw R&Dt > 5%, R&Dt=assetst 1 > 5%, and (R&Dt=assetst 1) > 5% . rbook (rintangible)
is the return on book equity (intangible assets) deﬁned as in Daniel and Titman (2006). Patents=R&D is
patents to lagged raw R&D (deﬁned as in Hirshleiefer, Hsu, and Li (2011)). Patents
R&D high (Patents
R&D low) refers
to stocks in the top (bottom) 30% in a given month. log(ME), log(B=M). r 12; 2, r 1, turnover, and 
are deﬁned as in table V. r 1, turnover, and  are controls in some regressions. The regressions only include
stocks with pricet 1 > 5. The sample period is July 1980 to December 2009. T-statistics are in parenthesis.
(1) (2) (3) (4) (5) (6) (7) (8)
R&Dhigh  abilityhigh 0.615 0.721 0.603 0.741 0.676 0.780 0.629 0.747
(2.31) (2.71) (2.30) (2.80) (2.49) (2.87) (2.38) (2.81)
R&Dhigh  abilitylow -0.147 -0.213 -0.198 -0.231 -0.125 -0.217 -0.152 -0.222
(-0.81) (-1.16) (-1.09) (-1.26) (-0.68) (-1.17) (-0.84) (-1.22)
abilityhigh -0.093 -0.053 -0.036 -0.023 -0.111 -0.058 -0.092 -0.054
(-1.33) (-0.91) (-0.55) (-0.39) (-1.56) (-1.00) (-1.29) (-0.93)
abilitylow -0.134 -0.100 -0.083 -0.069 -0.146 -0.098 -0.135 -0.093
(-1.84) (-1.60) (-1.23) (-1.12) (-1.95) (-1.56) (-1.80) (-1.49)
R&Dhigh 0.047 0.093 -0.058 -0.005 0.067 0.105 0.089 0.139
(0.30) (0.79) (-0.42) (-0.04) (0.40) (0.89) (0.54) (1.17)
R&Dlow -0.153 -0.077 -0.181 -0.142
(-2.21) (-1.18) (-2.55) (-1.98)
R&Dzero -0.838 -0.770 -1.082 -0.968
(-2.33) (-2.15) (-3.01) (-2.66)
log(ME) -0.026 -0.041 -0.025 -0.042 -0.036 -0.046 -0.050 -0.060
(-0.68) (-1.18) (-0.65) (-1.20) (-0.95) (-1.30) (-1.31) (-1.75)
log(B=M) 0.263 0.226 0.269 0.226 0.245 0.210
(3.86) (3.68) (4.07) (3.71) (3.58) (3.43)
r 12;2 0.771 0.791 0.756 0.784 0.714 0.706 0.785 0.805
(3.59) (4.03) (3.55) (4.01) (3.27) (3.55) (3.66) (4.10)
R&D
large
t 1 0.192 0.205
(1.72) (2.01)
R&D
large
t 5;t 1 0.302 0.344
(2.75) (3.89)
log(B=M)t 5 0.092 0.091
(1.55) (1.65)
rbook 0.014 -0.002
(0.25) (-0.03)
rintangible -0.221 -0.189
(-2.72) (-2.52)
Patents
R&D high -0.069 -0.062
(-0.66) (-0.56)
Patents
R&D low -0.333 -0.322
(-3.65) (-3.86)
Other Controls Yes Yes Yes Yes
Number of Months 354 354 354 354 354 354 354 354
Total Observations 290272 283031 290272 283031 284098 277350 290272 283031Table VIII
Annual Fama-MacBeth regressions of Logged Patents on R&D and Ability
The table presents annual Fama-MacBeth regressions of logged patents on R&D and R&D
Ability. The patent dependent variables are the following: patent stock, cite stock, patent
ﬂow, and cite ﬂow. Patent stock is the number of patents held by a ﬁrm in a given year
(where year refers to application year). Patent ﬂow is the number of new patents granted to
a ﬁrm based on the application year of the patent. Cite refers to the number of citations,
and cite stock and ﬂow are deﬁned analogously to patent stock and ﬂow. The functional
form of the dependent variables is the log of 1 + the raw variable. Ability is computed
as described in Table II. The R&D (Ability) used in the regressions is the R&D (Ability
estimate) from the ﬁscal year ending in calendar year t-1. abilityhigh equals one if a stock is
in the top quintile for a given month. The regressions include the following control variables:
log(ME), log(B/M), log(1+leverage), instown, and log(age). ME is market-cap at the end of
the previous year. B/M is lagged book to market computed as in Fama and French (1993).
leverage is book leverage divided by book equity lagged one year. instown is institutional
ownership from the previous year expressed as a fraction of shares outstanding. Age is the
age of the ﬁrm in years computed based on they ﬁrm’s ﬁrst appearance on CRSP. The sample
period is 1980 to 2006. T-statistic are in parenthesis.
Panel A: R&D lagged one period
Patent Cite Patent Cite Patent Cite Patent Cite
Stock Stock Flow Flow Stock Stock Flow Flow
log(1 + R&D)abilityhigh 11.96 16.70 9.07 14.87 9.18 12.61 6.99 11.31
(7.2) (6.8) (7.1) (6.8) (6.6) (6.1) (6.3) (6.2)
abilityhigh -0.63 -0.95 -0.45 -0.75 -0.52 -0.78 -0.37 -0.60
(-19.8) (-19.7) (-13.4) (-11.2) (-18.2) (-17.9) (-12.1) (-10.8)
log(1 + R&D) 2.21 3.10 1.94 3.16 1.92 2.68 1.81 2.90
(3.0) (3.0) (3.1) (3.0) (3.1) (3.0) (3.2) (3.1)
Controls Yes Yes Yes Yes Yes Yes Yes Yes
Industry Fixed Eﬀects Yes Yes Yes Yes
R
2
0.42 0.31 0.28 0.17 0.46 0.35 0.31 0.19
Number of Years 27 27 27 27 27 27 27 27
Total Observations 27464 27464 27464 27464 27464 27464 27464 27464
Panel B: Average R&D from t   5 to t   1
Patent Cite Patent Cite Patent Cite Patent Cite
Stock Stock Flow Flow Stock Stock Flow Flow
log(1 + R&D) 5;1abilityhigh 16.51 22.69 12.41 20.30 12.33 16.43 9.45 15.15
(9.2) (9.5) (10.4) (9.8) (8.6) (8.5) (9.6) (9.6)
abilityhigh -0.69 -1.05 -0.50 -0.83 -0.55 -0.83 -0.39 -0.65
(-28.1) (-24.6) (-16.6) (-13.2) (-22.7) (-19.0) (-15.0) (-12.9)
log(1 + R&D) 5; 1 1.94 2.62 1.62 2.63 1.78 2.42 1.55 2.52
(3.1) (2.9) (3.0) (2.9) (3.2) (3.1) (3.2) (3.1)
Controls Yes Yes Yes Yes Yes Yes Yes Yes
Industry Fixed Eﬀects Yes Yes Yes Yes
R
2
0.45 0.34 0.32 0.20 0.48 0.37 0.35 0.22
Number of Years 27 27 27 27 27 27 27 27
Total Observations 28625 28625 28625 28625 28625 28625 28625 28625Table IX
Annual Fama-MacBeth Regressions of New Products on R&D and Ability
This table presents annual Fama-MacBeth regressions of products on lagged R&D and lagged
Ability. Products is the number of new products introduced by a ﬁrm in a given ﬁscal
year. Ability is computed as described in Table II. abilityhigh equals one if a stock is in
the top quintile for a given month. The regressions include the following control variables:
products 5; 1, log(ME), log(B=M), log(1+leverage), instown, and log(age). products 5; 1
is the log of 1 + the average yearly number of new products measured over the past ﬁve years.
ME is market-cap at the end of the previous year. B/M is lagged book to market computed
as in Fama and French (1993). leverage is book leverage divided by book equity lagged one
year. instown is institutional ownership from the previous year expressed as a fraction of
shares outstanding. Age is the age of the ﬁrm in years computed based on they ﬁrm’s ﬁrst
appearance on CRSP. The sample period is 2000 to 2008. T-statistic are in parenthesis.
(1) (2) (3) (4) (5) (6)
log(1 + R&D)  abilityhigh 4.414 4.628 3.458
(2.73) (2.67) (2.36)
log(1 + R&D) 5; 1  abilityhigh 0.515 0.455 0.436
(7.54) (6.01) (3.17)
abilityhigh -0.367 -0.466 -0.313 -0.048 -0.053 -0.048
(-2.86) (-3.29) (-1.54) (-3.49) (-3.36) (-2.51)
log(1 + R&D) -0.058 -0.021 -0.177
(-0.87) (-0.26) (-1.81)
log(1 + R&D) 5; 1 -0.011 -0.013 -0.029
(-1.20) (-1.44) (-3.04)
products 5; 1 1.281 1.261 1.250 1.022 1.010 1.001
(47.90) (46.42) (45.94) (107.45) (95.76) (96.35)
log(ME) 0.152 0.163 0.012 0.013
(6.63) (6.68) (5.86) (5.83)
log(B=M) 0.137 0.214 0.005 0.011
(2.17) (2.98) (1.01) (2.05)
log(1 + leverage) 0.291 0.307 0.028 0.032
(2.85) (2.75) (2.27) (2.17)
log(instown) 0.599 0.754 0.074 0.098
(2.03) (2.41) (1.66) (1.92)
log(age) -0.256 -0.202 -0.022 -0.019
(-3.35) (-3.46) (-5.13) (-6.42)
Industry Fixed Eﬀects Yes Yes
R
2
0.87 0.87 0.87 0.81 0.82 0.82
Number of Years 9 9 9 9 9 9
Total Observations 6078 5992 5992 6185 6098 6098Table X
Tests of Mechanisms
This table presents monthly Fama-MacBeth (1973) regressions. The R&D (Ability estimate) used in the
regression is the R&D (Ability estimate) from the ﬁscal year ending in calendar year t   1 from July to De-
cember and calendar year t 2 from January to June (as in Fama and French (1993)). Ability is computed as
described in Table II. abilityhigh (abilitylow) equals one if a stock is in the top (bottom) quintile for a given
month. R&Dhigh (R&Dlow) equals one for a stock if its ability estimate is greater than the 70th (not greater
than the 30th) percentile in a given month. R&Dzero equals one if R&D = 0. guidance is the number of
times a ﬁrm issued earnings’ guidance in the previous 12 months. guidancehigh equals one if the stock is in
top 30% of guidance for a given month. founder equals one if the CEO is currently a founder. KZ is the
Kaplan-Zingales four variable (we exclude Q from the measure) ﬁnancial constraint measure (1997). KZmost
(KZmid) equals one if the stock is top 30% (middle 40%) of KZ for a given month. cash is deﬁned as cash
and short term investmests divided by lagged total assets. cashlow. (KZmid) equals one if the stock is
bottom 30% (middle 40%) of cash for a given month. CAPX is capital expenditures divided sales. OPEX
is operating expeditures divided by sales. The regressions use the following control variables: log(ME),
log(B=M), r 12; 2, r 1, turnover and . They are deﬁned as in table V. The regressions only include stocks
with lagged price greater than 5. The sample period is July 1980 to December 2009. T-statistics are in
parenthesis.
Panel A: Pooled regressions: Opacity Interaction (guidance)
R&Dhighabilityhigh R&Dhighabilityhighguidancehigh Controls
Estimate 1.553 -1.161 Yes
T-stat (3.52) (-1.53)
Panel B: Pooled regressions: Founder Interaction
R&Dhighabilityhigh R&Dhighabilityhighfounder Controls
Estimate 0.640 1.534 Yes
T-stat (1.38) (1.61)
Panel C: Pooled Regressions: Financial Constraint Interaction (KZx)
R&Dhighabilityhigh R&DhighabilityhighKZmid R&DhighabilityhighKZmost Controls
Estimate 0.450 0.692 1.415 Yes
T-stat (1.31) (1.20) (1.62)
Panel D: Pooled Regressions: Financial Constraint Interaction (Cash)
R&Dhighabilityhigh R&Dhighabilityhighcashmid R&Dhighabilityhighcashlow Controls
Estimate 0.732 0.013 0.427 Yes
T-stat (1.91) (0.02) (0.52)
Panel E: F-M Regression of returns on Ability and CAPX
CAPXhighabilityhigh abilityhigh CAPXhigh Controls
Estimate -0.127 -0.109 -0.051 Yes
T-stat (-1.05) (-1.44) (-0.61)
Panel F: F-M Regression of returns on Ability and OPEX
OPEXhighabilityhigh abilityhigh OPEXhigh Controls
Estimate -0.070 -0.131 -0.269 Yes
T-stat (-0.35) (-1.87) (-2.12)Appendix:
Misvaluing InnovationFigure A1
Annual Returns to Value-Weight Ability/R&D Spread Portfolio
This ﬁgure shows annual returns to high Ability/high R&D minus low Ability/High R&D
spread portfolios. Each month stocks with positive lagged R&D and non-missing lagged
Ability are sorted into quintiles for Ability and 30%/40%/30% breakpoints for R&D. Port-
folios are formed every month from the intersection of these two sorts. The R&D (Ability
estimate) used to form the portfolios is the R&D (Ability estimate) from the ﬁscal year end-
ing in calendar year t-1 from July to December and calendar year t-2 from January to June
(as in Fama and French (1993)). R&D is scaled by sales. Ability is computed as described in
Table II. The high Ability/high R&D (low Ability/high R&D) portfolio is formed from the
intersection of the top 20% (bottom 20%) of ability and top 30% of R&D. The ﬁgure also
show the annual excess return on a proxy for the market portfolio (VW portfolio of CRSP
common stock), and recession periods (as deﬁned by the NBER) are denoted by the gray
shaded areas.
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Value-Weight Ability/R&D Spread Portfolio
r -
spread = 11.5%
t-stat = 2.12
ρ(rspread,rM) = 0.11
Spread Return
rM-rfTable A1
Persistence in R&D Ability
The table reports the fraction of stocks that are in ability quintile x in year t given they are
in ability quintile x in year t   lag. Sepciﬁcally, it reports means of the time series of these
fractions for each quintile. The table also reports results from a simulation of 1,000 trials
where persistence is computed using an identical sample and methodology except R&D and
sales growth are replaced with standard normal random variables (i.e., the ability estimation
is just noise). R&D ability is computed for each ﬁrm every year using ﬁve (j = 1:::5) time
series regressions of sales growth on past R&D:
log(
Salesit
Salesit 1
) = 0 + jlog(1 + R&Dit j) + it
A back window of 6-8 years of non-missing data is required. An additional requirement is
that at least half of the R&D observations are non-zero. Ability is computed as the average
of the ﬁve slope coeﬃcients (j). The sample period is 1980 to 2009.
Mean Annual Persistence in Ability
Prob(Quintile = i), year = t if Quintile = i, year = t   lag
Ability Quintiles
Lag Low 2 3 4 High
1 0.66 0.50 0.51 0.49 0.70
2 0.48 0.37 0.40 0.36 0.55
3 0.38 0.32 0.35 0.29 0.46
4 0.30 0.30 0.32 0.26 0.39
5 0.26 0.28 0.30 0.24 0.36
Lag Simulation (runs=1,000): Ability Estimation is Noise
1 0.54 0.40 0.38 0.40 0.54
2 0.39 0.33 0.32 0.33 0.39
3 0.29 0.29 0.29 0.29 0.29
4 0.24 0.27 0.28 0.27 0.24
5 0.21 0.25 0.27 0.26 0.21Table A2
Double Sorts on R&D and Ability: Sub-Periods
This table presents monthly portfolio returns (in %) for sorts on Ability and R&D for various
sub-periods of the sample. Each month stocks with positive lagged R&D and non-missing
lagged Ability are sorted into quintiles for Ability and 30%/40%/30% breakpoints for R&D.
Portfolios are formed every month from the intersection of these two sorts. The R&D (Ability
estimate) used to form the portfolios is the R&D (Ability estimate) from the ﬁscal year ending
in calendar year t-1 from July to December and calendar year t-2 from January to June (as in
Fama and French (1993)). R&D is scaled by sales. Ability is computed as described in table
II. Characteristic abnormal returns are computed by adjusting returns using 125 (5x5x5)
size/book-to-market/momentum portfolios (computed as in DGTW (1997). The benchmark
portfolios’ weighting match the weighting of the R&D/Ability portfolios. All portfolios
(including the benchmark portfolios) also contain the restriction that lagged price must be
greater than $5 (breakpoints are computed before imposing the lagged price restriction).
The sample period is July 1980 to December 2009.
Panel A: Equal-Weight Portfolios
Size-B/M-Mom Adjusted Returns
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
July 1980 - June 1990
Mean 0.22 -0.04 -0.13 0.22 0.18 0.12 0.25
T-stat 1.91 -0.35 -0.60 2.22 1.60 0.28 0.55
July 1990 - June 2000
Mean -0.23 -0.04 -0.08 -0.16 0.02 1.14 1.21
T-stat -1.98 -0.30 -0.29 -1.59 0.18 3.17 3.67
July 2000 - December 2009
Mean -0.03 0.06 -0.50 0.05 0.08 0.85 1.35
T-stat -0.20 0.37 -1.30 0.36 0.47 1.72 2.78
Panel B: Value-Weight Portfolios
Size-B/M-Mom Adjusted Returns
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
July 1980 - June 1990
Mean 0.28 -0.01 -0.34 -0.11 0.18 0.12 0.46
T-stat 1.62 -0.11 -1.70 -0.77 1.11 0.28 1.01
July 1990 - June 2000
Mean 0.10 -0.07 -0.12 -0.03 0.22 1.03 1.15
T-stat 0.75 -0.38 -0.40 -0.26 1.32 2.44 2.45
July 2000 - December 2009
Mean 0.16 0.27 -0.54 0.14 0.27 0.88 1.42
T-stat 0.78 1.37 -1.34 0.82 0.95 1.34 1.85Table A3
Double Sorts on R&D and Ability: 5x2 Sort
The table presents monthly portfolio returns (in %) for sorts on Ability and R&D. Each
month stocks with positive lagged R&D and non-missing lagged Ability are sorted into
quintiles for Ability and 2 buckets based on median R&D. The R&D (Ability estimate) used
to form the portfolios is the R&D (Ability estimate) from the ﬁscal year ending in calendar
year t-1 from July to December and calendar year t-2 from January to June (as in Fama
and French (1993)). R&D is scaled by sales. Ability is computed as described in table
II. Characteristic abnormal returns are computed by adjusting returns using 125 (5x5x5)
size/book-to-market/momentum portfolios (computed as in DGTW (1997). The benchmark
portfolios’ weighting match the weighting of the R&D/Ability portfolios. All portfolios
(including the benchmark portfolios) also contain the restriction that lagged price must be
greater than $5 (breakpoints are computed before imposing the lagged price restriction).
The sample period is July 1980 to December 2009.
Panel A: Equal-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dhigh R&Dlow R&Dhigh Spread
Excess Returns
Mean 0.77 0.75 0.79 1.19 0.43
T-stat 2.89 2.14 2.92 3.18 2.76
Size-B/M-Mom Adjusted Returns
Mean -0.09 0.01 -0.04 0.56 0.55
T-stat -1.14 0.06 -0.58 3.66 3.70
Number of Stocks
Mean 123 54 155 29
Panel B: Value-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dhigh R&Dlow R&Dhigh Spread
Excess Returns
Mean 0.71 0.55 0.58 0.98 0.44
T-stat 2.86 1.73 2.23 2.68 1.76
Size-B/M-Mom Adjusted Returns
Mean 0.12 -0.04 -0.03 0.54 0.58
T-stat 1.40 -0.29 -0.37 3.04 2.81
Number of Stocks
Mean 123 54 155 29Table A4
Double Sorts on R&D and Ability: 4x4 Sort
This table presents monthly portfolio returns (in %) for sorts on Ability and R&D. Each
month stocks with positive lagged R&D and non-missing lagged Ability are sorted into
quartiles for Ability and quartiles for R&D. Portfolios are formed every month from the
intersection of these two sorts. The R&D (Ability estimate) used to form the portfolios is
the R&D (Ability estimate) from the ﬁscal year ending in calendar year t-1 from July to
December and calendar year t-2 from January to June (as in Fama and French (1993)). R&D
is scaled by sales. Ability is computed as described in table II. Characteristic abnormal re-
turns are computed by adjusting returns using 125 (5x5x5) size/book-to-market/momentum
portfolios (computed as in DGTW (1997). The benchmark portfolios’ weighting match the
weighting of the R&D/Ability portfolios. All portfolios (including the benchmark portfo-
lios) also contain the restriction that lagged price must be greater than $5 (breakpoints are
computed before imposing the lagged price restriction). The sample period is July 1980 to
December 2009.
Panel A: Equal-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.83 0.74 0.57 0.78 0.84 1.27 0.70
T-stat 3.14 2.57 1.29 2.94 2.85 2.46 2.61
Size-B/M-Mom Adjusted Returns
Mean -0.07 -0.05 -0.17 -0.05 0.05 0.78 0.95
T-stat -0.72 -0.60 -0.90 -0.67 0.72 2.67 3.57
Number of Stocks
Mean 77 113 29 108 106 13
Panel B: Value-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.66 0.66 0.40 0.60 0.59 1.11 0.71
T-stat 2.50 2.71 0.98 2.39 1.89 2.45 1.79
Size-B/M-Mom Adjusted Returns
Mean 0.12 0.11 -0.14 -0.07 0.06 0.70 0.84
T-stat 1.11 1.28 -0.69 -0.69 0.63 2.38 2.43
Number of Stocks
Mean 77 113 29 108 106 13Table A5
Double Sorts on R&D and Ability: Alternate Regression Ability Measure
The table presents monthly portfolio returns (in %) for sorts on Ability and R&D. Each
month stocks with positive lagged R&D and non-missing lagged Ability are sorted into
quintiles for Ability and 30%/40%/30% breakpoints for R&D. Portfolios are formed every
month from the intersection of these two sorts. The R&D (Ability estimate) used to form
the portfolios is the R&D (Ability estimate) from the ﬁscal year ending in calendar year t-1
from July to December and calendar year t-2 from January to June (as in Fama and French
(1993)). R&D is scaled by sales. Ability is computed for each ﬁrm every year using the
time series regressions of sales growthit on R&Di;t 1;t 5. A back window of 6-8 years of
non-missing data is required. Ability is deﬁned as the slope coeﬃcient from the regression.
An additional requirement is that at least half of the R&D observations are non-zero. All
portfolios also contain the restriction that lagged price must be greater than $5. The sample
period is July 1980 to December 2009.
Panel A: Equal-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.87 0.72 0.52 0.75 0.89 1.24 0.72
T-stat 3.22 2.45 1.16 2.77 2.92 2.48 2.51
Size-B/M-Mom Adjusted Returns
Mean 0.00 -0.12 -0.15 -0.11 0.10 0.78 0.93
T-stat 0.04 -1.20 -0.69 -1.44 1.14 2.72 3.15
Panel B: Value-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.64 0.52 -0.09 0.55 0.71 1.14 1.23
T-stat 2.49 1.72 -0.18 2.16 2.16 2.33 2.80
Size-B/M-Mom Adjusted Returns
Mean 0.12 -0.16 -0.22 -0.09 0.20 0.60 0.82
T-stat 1.06 -1.13 -0.80 -0.88 1.54 2.09 2.11Table A6
Double Sorts on R&D and Ability: Non-Regression Ability Measure
This table presents monthly portfolio returns (in %) for sorts on Ability and R&D. Each month
stocks with positive lagged R&D and non-missing lagged Ability are sorted into quintiles for Ability
and 30%/40%/30% breakpoints for R&D. Portfolios are formed every month from the intersection
of these two sorts. The R&D used to form the portfolios is the R&D from the ﬁscal year ending in
calendar year t-1 from July to December and calendar year t-2 from January to June (as in Fama
and French (1993)). Ability is lagged one year relative to R&D. R&D is scaled by sales. Ability is
computed as follows:
Ability =
1
8
8 X
j=1
log

Salest j
Salest j 1

[R&D=Sales]t j 1;t j 6
All portfolios also contain the restriction that lagged price must be greater than $5. The sample
period is July 1980 to July 2008.
Panel A: Equal-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.83 0.78 0.30 0.73 0.69 1.33 1.03
T-stat 2.95 2.30 0.57 2.92 2.04 2.13 2.28
Size-B/M-Mom Adjusted Returns
Mean 0.01 -0.01 -0.18 -0.11 -0.02 0.42 0.61
T-stat 0.06 -0.05 -0.70 -1.49 -0.26 1.09 1.49
Panel B: Value-Weight Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.80 0.66 0.54 0.63 0.40 1.37 0.83
T-stat 2.67 2.31 1.13 2.49 1.06 2.03 1.46
Size-B/M-Mom Adjusted Returns
Mean 0.12 0.06 -0.02 -0.05 -0.10 0.55 0.58
T-stat 0.63 0.46 -0.09 -0.58 -0.63 1.27 1.20Table A7
Double Sorts on R&D and Ability: Full 3x5
This table presents monthly portfolio returns (in %) for double sorts on Ability and R&D.
Each month stocks with positive lagged R&D and non-missing lagged Ability are sorted
into quintiles for Ability and 30%/40%/30% breakpoints for R&D. Portfolios are formed
every month from the intersection of these two sorts. The R&D (Ability estimate) used to
form the portfolios is the R&D (Ability estimate) from the ﬁscal year ending in calendar
year t-1 from July to December and calendar year t-2 from January to June (as in Fama
and French (1993)). R&D is scaled by sales. Ability is computed as described in Table II.
Characteristic abnormal returns are computed by adjusting returns using 25 size/book-to-
market portfolios’ (computed as in Fama and French (1993)). The benchmark portfolios
weighting match the weighting of the R&D/Ability portfolios. All portfolios (including the
benchmark portfolios) also contain the restriction that lagged price must be greater than $5
(breakpoints are computed before imposing the lagged price restriction). The sample period
is July 1980 to December 2009.
Panel A: Excess Returns of Equal Weight Portfolios
Ability Mean T-stats
Quintile R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh
Low 0.81 0.75 0.62 3.04 2.61 1.48
2 0.87 0.85 0.73 2.96 2.86 1.74
3 0.70 0.83 0.79 2.19 2.71 1.77
4 0.74 0.91 0.80 2.58 3.06 1.90
High 0.80 0.83 1.35 3.00 2.81 2.76
Spread 0.73 2.61
Panel B: Size-B/M-Adjusted Returns of Equal Weight Portfolios
Ability Mean T-stats
Quintile R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh
Low -0.07 -0.04 -0.10 -0.86 -0.43 -0.50
2 -0.01 0.13 0.13 -0.05 1.35 0.81
3 0.03 0.10 0.25 0.14 1.01 1.19
4 -0.10 0.15 0.22 -0.84 1.56 1.29
High -0.03 0.08 0.79 -0.42 0.90 2.84
Spread 0.89 3.32
Panel C: Number of Stocks
Ability Mean
Quintile R&Dlow R&Dmid R&Dhigh
Low 83 69 25
2 24 70 65
3 16 58 73
4 36 85 43
High 114 60 10Table A8
Double Sorts on R&D and Ability: International Stocks
This table presents monthly portfolio returns (in %) for double sorts on Ability and R&D for an
international sample of stocks (UK, Japan, and Germany). Each month stocks with positive lagged
R&D and non-missing lagged Ability are sorted into quartiles for Ability and quartile breakpoints
for R&D. Portfolios are formed every month from the intersection of these two sorts. The R&D
(Ability estimate) used to form the portfolios is the R&D (Ability estimate) from the ﬁscal year
ending in calendar year t-1 from July to December and calendar year t-2 from January to June
(as in Fama and French (1993)). R&D is scaled by sales. abilityhigh (abilitylow) equals one if a
stock is in the top (bottom) quartile for a given month. R&Dhigh (R&Dlow) equals one for a stock
if its Ability estimate is in the top (bottom) quartile in a given month. For this international
sample, the R&D and Ability breakpoints are computed separately for each country. All portfolios
also contain the restriction that lagged price must be greater than the 5th percentile (by month).
Average abnormal returns are also computed using the four factor model (Carhart (1997)). We use
Ken French’s international factors in the factor model regressions. The sample period is July 1995
to December 2010 (except for the case of German stocks, for which the sample period is July 2007
to December 2010).
Panel A: Equal-Weight International Portfolios
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh Spread
Excess Returns
Mean 0.26 0.49 0.39 0.27 0.52 1.23 0.84
T-stat 0.64 1.19 0.91 0.61 1.26 2.84 3.21
Global Four Factor Model 
 -0.20 0.10 0.05 -0.18 0.06 0.68 0.63
T-stat -0.62 0.37 0.16 -0.51 0.23 2.15 2.37
Panel B: Number of Stocks
Low Ability High Ability
R&Dlow R&Dmid R&Dhigh R&Dlow R&Dmid R&Dhigh
Mean 97 73 56 78 44 20Table A9
F-M Regressions Using Condtional Ability and R&D Sorts
This table presents monthly Fama-MacBeth (1973) regressions of returns on R&D and Ability. The
R&D (Ability estimate) used in the regression is the R&D (Ability estimate) from the ﬁscal year
ending in calendar year t 1 from July to December and calendar year t 2 from January to June
(as in Fama and French (1993)). Ability is computed as described in Table II. abilityhigh equals one
if a stock is in the top quintile/quartile/30% percent for a given month. R&Dhigh equals one for
a stock if its R&D is in the top quartile/quintile/30% percent breakpoint of the respective ability
portfolio bin (conditional sorting). log(ME) is the log of month t   1 market-cap, and log(B=M)
is log book to market deﬁned and lagged as in Fama and French (1993). r 12; 2 is the return from
month t   12 to month t   2. r 1 is the one month lagged return. turnover is average daily share
turnover (100) over the past year.  is the standard deviation of daily returns over the past year.
The regressions only include stocks with lagged price greater than 5. The sample period is July
1980 to December 2009. T-statistics are in parenthesis.
5x5 Sort 4x4 Sort 3x3 Sort
R&Dhigh  abilityhigh 0.403 0.428 0.413 0.394 0.296 0.254
(2.29) (2.51) (2.81) (2.68) (2.32) (2.02)
abilityhigh -0.107 -0.134 -0.112 -0.142 -0.072 -0.107
(-1.31) (-1.97) (-1.49) (-2.23) (-1.02) (-1.78)
R&Dhigh 0.027 0.105 0.002 0.077 0.089 0.163
(0.15) (0.74) (0.01) (0.59) (0.53) (1.27)
log(ME) -0.031 -0.039 -0.031 -0.041 -0.031 -0.043
(-0.80) (-1.14) (-0.81) (-1.17) (-0.79) (-1.23)
log(B=M) 0.242 0.198 0.241 0.196 0.246 0.196
(3.37) (3.20) (3.39) (3.15) (3.48) (3.17)
r 12;2 0.787 0.797 0.783 0.793 0.769 0.792
(3.55) (4.01) (3.54) (3.99) (3.49) (3.98)
r 1 -3.735 -3.729 -3.749
(-8.22) (-8.20) (-8.27)
turnover -0.299 -0.292 -0.292
(-1.65) (-1.61) (-1.62)
 -0.106 -0.110 -0.117
(-1.56) (-1.62) (-1.73)
Number of Months 354 354 354 354 354 354
Total Observations 290271 283030 290271 283030 290271 283030
Stocks per month in R&Dhigh  abilityhigh 33 32 52 50 74 72